,Entity,Cluster
57,2HG,0
1855,HT7,0
1856,HVA,0
2398,Mer,0
1863,Hb,0
1845,HRV,0
4185,hFABP,0
1828,HF,0
65,4-HNE,0
1257,DA metabolite HVA,0
1844,HR,0
3768,WMH (Fazekas score),1
2146,KBIT-2 verbal raw score,1
2244,Lumosity game scores,1
1847,HS scores,1
2706,PAL scores,1
2647,Omnibus Scores (Omn),1
944,COI scores,1
1589,Five Time Sit-to-Stand test (FTSS) score,1
4214,inaccuracy score,1
2145,KBIT-2 nonverbal raw score,1
2062,Imagined Timed 'Up & Go' (iTUG) score,1
4344,omnibus scores,1
1846,HS score,1
110,ACE total score,1
3545,Test time score,1
4574,thioflavin S,2
3569,Thioflavin T,2
1582,Fibrin,2
1583,Fibrinogen,2
3568,Thioflavin S,2
2514,NINCDS/ADRDA criteria,3
1743,Gd-DOTA concentration,3
2523,NMDS criteria,3
3536,Temporal Decline Percentage (TDP),3
10,129Xe retention parameter,3
1764,Global Deterioration Scale (GDS) score,3
1592,Florbenazine,4
1602,Flortaucipir SUVr,4
4141,florbenazine SUVr,4
4146,flortaucipir,4
4147,flortaucipir SUVr,4
4140,florbenazine,4
1601,Flortaucipir,4
3843,[11C]PIB,5
3845,[11C]PiB PET,5
4,11C-PiB,5
2865,PiB-positive individuals,5
2864,PiB-PET,5
2863,PiB load,5
2861,PiB,5
3878,[C11]PiB PET,5
2734,PET,5
2737,PET-PiB,5
2755,PILRB,5
2750,PIB-PET,5
2749,PIB imaging,5
2748,PIB,5
3766,WM volume,6
3773,WMH volume,6
4160,fusiform volume,6
1436,ERC volume,6
3588,Total WM volume,6
1276,DG volume,6
1437,ERC volume loss,6
3589,Total WMH volume,6
1688,GM volume,6
3582,Total GM volume,6
1820,HATA volume,6
1927,Hit rate,7
4103,double support percentage,7
4104,double support time,7
1928,Hit-rate,7
3925,anti-Aβ antibodies,8
222,APP and Aβ,8
549,Aβ deposition,8
550,Aβ deposition on PET,8
561,Aβ plaque,8
4393,pGlu-Aβ,8
551,Aβ depositions,8
558,Aβ pathology,8
555,Aβ load,8
2883,Plasma Aβ seeding activity,8
553,Aβ levels,8
552,Aβ deposits,8
1208,Cortical Aβ,8
654,Aβ−,8
646,AβPP,8
548,Aβ burden,8
540,Aβ Protein,8
562,Aβ plaque deposition,8
563,Aβ plaques,8
565,Aβ positivity,8
566,Aβ protein,8
567,Aβ protein precursor (AβPP),8
570,Aβ seeding activity,8
539,Aβ PET,8
575,Aβ+,8
582,Aβ-specific antibody titers,8
2738,PET-quantified Aβ,8
531,Aβ,8
541,Aβ SUVR,8
542,Aβ accumulation,8
547,Aβ biomarkers,8
577,Aβ-PET,8
568,Aβ proteins,8
1734,Gamma spectral power,9
1732,Gamma oscillations,9
4166,gamma oscillations,9
4165,gamma activity,9
3288,Spectral power distribution,9
2327,MRI scans,10
2332,MRI-derived measures,10
2330,MRI-based biomarkers,10
2323,MRI measures,10
2322,MRI measurements,10
2319,MRI findings,10
2318,MRI biomarkers,10
2313,MRI Biomarkers,10
2310,MRI,10
3332,Structural MRI,10
3967,brain MRI,10
2333,MRI-derived structural measures,10
2354,Magnetic Resonance Imaging (MRI),10
1638,Fronto-Parietal Network (FPN),11
1517,FCRT,11
1553,FPG,11
1542,FFA,11
1563,FYN,11
1554,FPN,11
1660,Fyn,11
1518,FCSRT,11
1543,FFG,11
3754,WASO,12
1427,ELoc,12
1458,Eloc,12
4113,eNOS,12
4211,iNOS,12
1761,Glia-derived nexin (GDN),13
1762,Glial activation biomarkers,13
1763,Glial fibrillary acidic protein (GFAP),13
2894,Plasma GFAP,13
4060,cerebrospinal fluid (CSF) GFAP levels,13
4435,plasma GFAP levels,13
1022,Cathepsin L,14
1016,Catalase,14
3992,cathepsin L,14
3991,cathepsin B,14
3990,catalase,14
1021,Cathepsin B,14
2528,NOS,15
1839,HOMA-B,15
1663,GABA,15
1813,Guanfacine,15
327,Akkermansia,15
3832,Yokukansan,15
1840,HOMA-IR,15
2529,NOSGER,15
2618,Norton scale,16
1696,GR/GPx ratio,16
3200,SUVr (Standardized Uptake Value Ratio),16
3301,Standardized Uptake Value (SUV),16
2339,MTA-scale,16
1642,Frontotemporal behaviour scale,16
1811,Grober–Buschke scale,16
2469,Motor Threshold (MT),16
3818,Word Typicality,17
1389,Dubois’ five-word test,17
1590,Five-word test,17
3821,Words per clause,17
3820,Word-finding difficulties,17
3068,Repeated Words,17
1206,Correct-word scores,17
4585,typical word usage,17
362,Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory,18
353,Alzheimer type neuropathologic change,18
351,Alzheimer Disease Cooperative Study–Activities of Daily Living (ADCS-ADL),18
459,Anti-dementia drugs,18
364,Alzheimer’s disease,18
363,Alzheimer’s Disease Cooperative Study—Activity of Daily Living total score,18
1569,Family history of dementia,18
118,AD pathology,18
120,AD-GRS (Alzheimer's Disease Genetic Risk Score),18
4602,weight loss,19
2639,Obesity,19
3785,Weight,19
777,Body weight,19
3786,Weight loss,19
3597,Total fat mass,19
2823,Peripheral adiposity,19
708,BMI,19
776,Body Mass (BM),19
3653,Tyrobp,20
2164,LAL,20
3124,SBD,20
3125,SBP,20
3498,TYROBP,20
732,Behavior Rating Scale for dementia,21
1140,Clinical Dementia Rating scale,21
1261,DAD scores,21
2995,Quick dementia Rating Scale (QDRS),21
357,Alzheimer's Mood Scale,21
1330,Dementia Mood Assessment Scale,21
358,Alzheimer’s Disease Assessment Scale,21
1205,Cornell Scale for Depression in dementia,21
1366,Disability Assessment dementia (DAD) scale,21
1365,Disability Assessment dementia (DAD),21
2363,Mattis dementia Rating Scale (DRS),21
1367,Discomfort Scale - dementia of Alzheimer Type,21
3391,TBV,22
3389,TBARS,22
2250,MADRS,22
160,AIS,22
1442,ESS,22
1562,FUS,22
3032,ROS,22
3336,Subcortical white-matter hyperintensities,23
4183,grey matter atrophy,23
3808,"White matter microstructure metrics (FA, MD, Da, Dr, ICVF, OD)",23
1373,Disruption of limbic white matter pathways,23
2216,Lesions Load,23
3805,White matter imaging markers,23
3795,White matter atrophy,23
3799,White matter hyperintensities (WMH) in the splenium of the corpus callosum,23
3777,WML (White Matter Lesions),23
3802,White matter hyperintensity lesions,23
1349,Diffusion tensor imaging measures of white matter integrity,23
1806,Grey matter atrophy,23
3806,White matter integrity,23
3798,"White matter hyperintensities (WMH) in the posterior corpus callosum, parietal, occipital, and frontal areas",23
4289,miR-623,24
4288,miR-5682,24
4287,miR-543,24
4286,miR-495-3p,24
4285,miR-4761-3p,24
4291,miRNA-146a,24
4272,miR-124,24
4273,miR-155,24
4274,miR-16,24
4275,miR-16-5p,24
4276,miR-19a-5p,24
4277,miR-2467-3p,24
4278,miR-25802,24
4279,miR-301a-3p,24
4280,miR-3132,24
4281,miR-411-5p,24
4284,miR-4649-5p,24
4290,miR-862-3p,24
4283,miR-4513,24
4282,miR-4303,24
2442,Mir107,24
4292,miRNA-33,24
4293,miRNAs,24
1426,ELISA Anti-HIV Test,25
1455,Elecsys® immunoassay,25
70,4G8 antibody,25
2047,IgG Antibodies,25
2049,IgG antibodies,25
1269,DC8E8 antibody,25
2050,IgG antibody levels,25
2054,IgG1 and IgG3 antibodies,25
1975,IFNγ,26
2111,Interferon-γ,26
2109,"Interferon gamma induced protein 10 [IP-10, CXCL10]",26
2110,Interferon-gamma [IFN-γ],26
1972,IFN-γ,26
4637,γH2AX,26
2021,INF-γ,26
1973,IFN-γ secretion,26
2022,INFγ,26
3025,RMR (Resting Metabolic Rate),27
4248,lower resting cortical metabolism,27
285,PCUN metabolism,27
4122,energy expenditure,27
1746,Generalized low uptake on SPECT/PET perfusion/metabolism scan,27
281,PCC metabolism,27
1237,Ctrough (Plasma drug concentration),27
2400,Metabolic Syndrome (MetS),27
2399,"MetS components (waist circumference, triglyceride, HDL, hypertension, fasting glucose)",27
428,metabolism intensity,27
2998,RAB27A,28
3000,RAK1,28
3004,RAVL,28
3006,RAVLT Del,28
3043,Rac1,28
3042,Rab7,28
3041,Rab3,28
3005,RAVLT,28
2747,PI3K,29
2223,Lgals3,29
2166,LAMP2,29
2165,LAMP1,29
4420,phospho-PI3K,29
4642,λk3,29
3780,WMS-VR,30
2795,PWMH,30
3779,WMS-III,30
3762,WM,30
3815,Wnt signaling,30
3763,WM alterations,30
3781,WST,30
3764,WM degeneration,30
3816,Wnt3,30
3767,WMH,30
3769,WMH accumulation,30
3770,WMH burden,30
3753,WAM,30
3772,WMH progression,30
3775,WMHs,30
3774,WMHV,30
1304,DWMH,30
378,WMH presence,30
4342,oVEMP,31
322,AgRP,31
2634,OEF,31
1940,Huperzine A,31
2632,OA,31
4489,sMRI,31
2631,O3PUFA,31
4255,mSOA,31
1698,GRP78,32
1669,GAD,32
1681,GFAP,32
1680,GDS,32
1679,GDNF,32
184,Gad67,32
1678,GDN,32
1670,GAD67,32
1697,GRN,32
1676,GCLC,32
1872,Helicobacter,33
2246,Lycium barbarum extract,33
1873,Helicobacteraceae,33
335,Allobaculum,33
2924,Polygonum multiflorum Thunb.,33
4243,locus coeruleus (LC),33
736,Benson Figure Copy,33
1736,Gantenerumab,33
2086,Infliximab,33
1729,Gallic Acid,34
2563,Nervonic acid,34
1936,Homovanillic Acid,34
815,Butyric acid,34
1581,Ferulic acid,34
3672,Urea,34
1730,Gallic acid,34
2958,Propionic acid,34
2479,Myristic acid,34
3673,Uric acid,34
3176,SOM,35
3173,SOD1,35
3177,SORCS1,35
3174,SOD2,35
3175,SOD3,35
3172,SOD activity,35
3284,Souvenaid,35
318,SOD,35
3283,Sorcs1,35
3178,SORL1,35
4126,entorhinal volume,36
4087,cortical thickness of the entorhinal cortex,36
4125,entorhinal cortex thickness,36
4124,entorhinal cortex,36
1220,Cortical thickness in entorhinal cortex,36
1467,Entorhinal (% TIV),36
1468,Entorhinal Cortical Thickness,36
1469,Entorhinal cortex thickness,36
1470,Entorhinal cortex volume,36
148,Entorhinal cortical thickness,36
1472,Entorhinal thickness,36
1473,Entorrhinal cortex volume,36
1421,EFE+,37
1425,EGlob,37
1420,EFE,37
1444,EWS,37
1403,ECog,37
1424,EGCG,37
1450,Egr3,37
1449,Egr-3,37
1448,Eglob,37
1423,EFEs+,37
3207,SWF,38
3206,SWA,38
3119,SAFr,38
3161,SLIs,38
3162,SLUMS,38
3118,SAA,38
3160,SLI,38
4244,lowSWA,38
4246,lowSWE,38
1957,I2BS,39
2501,NCAM2,39
1958,I2PP2A,39
3496,TXB2,39
2727,PEN2,39
3147,SHIP2,39
869,CD2AP SNP rs9349407,39
2554,Navβ2,39
936,CMRO2,39
868,CD2AP,39
2643,Olig2,39
3513,Tau deposition,40
4360,p-tau depositions,40
3518,Tau isoforms,40
3515,Tau formation,40
4548,tau oligomers,40
3516,Tau fragments,40
2262,MC1 (conformationally changed Tau),40
4550,tau peptide fragments,40
3512,Tau aggregates,40
1195,Conformationally changed Tau (MC1),40
3511,Tau accumulation,40
1177,Cognitive tests,41
2465,Montreal Cognitive Assessment (MoCA),41
1192,Composite z-scores for cognitive function,41
4072,cognitive assessments,41
1176,Cognitive test scores,41
1174,Cognitive scores (MMSE),41
1173,Cognitive scores (ADAS-Cog11),41
4076,cognitive measures,41
4077,cognitive performance,41
1158,Cognitive Level (MMSE),41
1172,Cognitive score,41
4173,global cognitive status,41
4329,neurocognitive measures,41
2464,Montreal Cognitive Assessment,41
1161,Cognitive composite score,41
1768,Global cognitive score,41
315,Addenbrooke's Cognitive Examination (ACE) VL/OM ratio,41
1164,Cognitive disorders examination test (CODEX),41
1166,Cognitive function (ADAS-cog),41
1169,Cognitive performance,41
1163,Cognitive disorders examination test,41
2142,Jmild cognitive impairment S score,41
3169,SO power,42
741,Beta band,42
339,Alpha power,42
338,Alpha oscillatory power,42
336,Alpha band,42
743,Beta power,42
1311,Decreased beta-band power,42
1310,Decreased alpha-band power,42
337,Alpha oscillations,42
1409,EEG alpha power,42
19,18F-FDG,43
3852,[18F]-fluoro-deoxyglucose PET (FDG-PET),43
21,18F-FDG PET,43
1608,Fluorodeoxyglucose (FDG),43
38,18F-fluorodeoxyglucose,43
23,18F-FDG-PET,43
41,18FDG,43
42,18FDG-PET,43
1207,Cortical AD signature,44
1209,Cortical Plasticity,44
1215,Cortical plasticity,44
1217,Cortical tau load,40
4082,cortical tau,44
1225,Cortico-motor reactivity,44
1224,Cortico-motor plasticity,44
3452,TRPA1,45
3454,TRx0237,45
3609,TrKA,45
3453,TRPML1,45
3643,TrkA,45
3644,TrkA Mono,45
1867,Hcy (Homocysteine),46
1613,Folate,46
1614,Folic Acid,46
1935,Homocysteine (Hcy),46
1934,Homocysteine,46
4455,proportions of pronouns,47
4080,content density,47
4212,idea density,47
4456,proportions of verbs,47
4109,eCarb (digestible carbohydrates),48
4108,eCarb,48
1234,Crenezumab,48
283,Acarbose,48
1402,ECbche,48
957,CREB,48
4589,vAβ,49
992,CVLT-II,49
3688,VIP,49
3985,cVEMP,49
4588,vAChT,49
3689,VIP interneurons,49
3698,VR-DOT,49
991,CVFT,49
3734,Visual Analog Scale (VAS),49
1431,EQ VAS,49
3210,Saccular function,50
3674,Utricular function,50
3733,Vestibular loss,50
2859,Physical function,50
4598,vestibular function,50
3228,Semicircular canal function,50
3966,bone health,51
3237,Serum calcium concentration,51
778,Bone Mineral Density (BMD),51
3236,Serum calcium,51
4233,left fusiform gyrus (L FFG),52
4475,right middle temporal gyrus,52
4238,left middle temporal gyrus (MTG),52
2205,Left Middle Temporal Gyrus (L MTG),52
3100,Right Middle Temporal Gyrus (R MTG),52
1063,Cerebral blood flow (CBF) in left middle temporal gyrus (MTG),52
2199,Left Fusiform Gyrus (L FFG),52
2206,Left angular gyrus,52
2207,Left angular gyrus (AG) atrophy,52
3105,Right middle temporal gyrus (RMTG) hypometabolism,52
3106,Right middle temporal gyrus (RMTG) metabolism,52
2234,Local Gyrification Index (LGI),52
2709,PARP1,53
4412,parvalbumin,53
2810,Parvalbumin (PV),53
2809,Parvalbumin,53
2802,Parietal Activation,53
2708,PARP,53
1012,Carbohydrate intake,54
916,CFr (carbohydrate/fat ratio),54
4110,eFat,54
4111,eFat (total fat),54
1168,Cognitive intra-individual variability (IIV),55
2117,Intraindividual Variability (IIV),55
3190,SRT variance,55
284,Acceleration variance,55
3634,Trial-to-trial CRT variance,55
2953,Progranulin,56
2868,Pioglitazone,56
3445,TOMM40,56
2866,Piezo1,56
3400,TEMPOL,56
1586,Firmicutes,56
3493,TUNEL,56
2751,PICALM,56
4452,proNGF,56
2968,Protofibrils,56
3253,Skin color,57
4172,girl is,57
3033,ROSA,57
1196,Congo red,57
1392,Dysphoria,57
1490,Euphoria,57
1324,Delta band,58
1325,Delta band activity,58
1326,Delta frequency band,58
1323,Delta Power,58
1327,Delta power,58
2072,Increased delta-band power,58
4096,delta band functional connectivity,58
1538,FDG-SUVR,59
1537,FDG-ROI,59
1535,FDG-PET uptake,59
1534,FDG-PET measures,59
1533,FDG-PET markers,59
1528,FDG-PET SUVRs,59
1527,FDG-PET SUVR,59
1525,FDG-PET,59
1523,FDG SUVR,59
1521,FDG PET SUVR,59
1520,FDG PET,59
1519,FDG,59
3469,TUG (Timed Up-and-Go) Test,60
3476,TUGdt (Dual-task Test),60
3468,TUG (Timed Up and Go),60
3466,TUG,60
3470,TUG dual-task test (TUGdt),60
3490,TUGdt test outcomes,60
348,TUG single-task,60
3472,TUG time,60
2820,Performed Timed 'Up & Go' (TUG) score,60
3467,TUG (Timed Up and Go test),60
1682,GIP,61
1683,GIP analogs,61
4528,t-PrP,61
2155,Kp,61
2167,LBP,61
3395,TDP,61
2187,LTP,61
3393,TC-PTP,61
2152,Kgp,61
2773,PRP,61
677,BAX,62
676,BAVLT,62
673,BAM-10,62
674,BAM-10 antibody,62
660,BA35 volume,62
662,BA9,62
661,BA46,62
2010,IL-8/CXCL8,63
1291,DO 80,63
1268,DC8E8,63
2637,OPA1,63
4115,eea1,63
1430,EPS8,63
1010,Calretinin,64
783,Bradykinin,64
2558,Neopterin,64
4325,neocortex,64
4169,genistein,64
1113,Chemokines,64
2908,Plasma genistein,64
4328,neurocan,64
3691,VLD (pixel-wide vessel density),65
2822,Peripapillary RPC VD,65
3731,Vessel Length Density (VLD),65
3730,Vessel Density (VD),65
2412,Microcapillary VD,65
3732,Vessel density (VD),65
4497,scFv D5,66
3127,SCD,66
3132,SCFAs,66
3129,SCD-Q,66
4496,scFv D10,66
3134,SCOT,66
3130,SCFA,66
3126,SCAG,66
2987,QUICKI,67
2058,IgM,67
2025,INSR,67
2040,IVIG,67
2549,NSE,67
2092,Insula,67
2038,ISI,67
2023,INI,67
1968,IDE,67
2041,IWIs,67
1754,Ghrelin,68
1770,GluR1,68
1687,GLUT4,68
4170,ghrelin,68
1686,GLUT1,68
1013,Cardiorespiratory fitness,69
809,Breathing patterns,69
3987,cardiorespiratory fitness,69
506,Asthma,69
328,Smoking,69
2586,Neuroplasticity,70
4068,circuitousness,70
2504,NEUROTICISM,70
3230,Sensorimotor network,70
3142,SENSORIMOTOR SYNCHRONIZATION (SMS),70
3499,Tactile Domain,70
4336,neuronal viability,70
1478,Epilepsy,70
377,Amyloid,8
386,Amyloid PET biomarkers,8
2872,Pittsburgh compound B (PiB) amyloid imaging,8
379,Amyloid (D54D2),8
383,Amyloid Centiloid,8
394,Amyloid Precursor Protein (APP),8
529,Aß amyloid deposits,8
3895,amyloid,8
3900,amyloid accumulation,8
3904,amyloid deposition,8
3905,amyloid pathology,8
3909,amyloid precursor protein,8
3912,amyloid-beta deposits,8
784,Brain Amyloid Burden,8
3996,cerebral amyloid,8
39,18F-flutemetamol (amyloid-β),8
428,Amyloid β precursor protein,8
423,Amyloid tracer uptake,8
422,Amyloid status,8
420,Amyloid precursor protein (APP),8
413,Amyloid neuropathology,8
412,Amyloid levels,8
411,Amyloid deposits,8
410,Amyloid deposition,8
408,Amyloid burden,8
407,Amyloid biomarkers,8
397,Amyloid accumulation,8
3556,Thal amyloid phase,8
4097,dendritic cells,72
808,BrdU-positive cells,72
3494,TUNEL-positive cells,72
2089,Innate immunity signaling,72
2360,Mast cells,72
2553,Natural killer cells,72
3303,Stem cells,72
1548,FJB-positive cells,72
1112,ChAT immuno-positive neurons,72
3983,c-kit-positive cells,72
4221,insulin sensitivity,73
2994,Quantitative insulin sensitivity check index (QUICKI),73
2095,Insulin,73
2097,Insulin Resistance,73
2098,Insulin Resistance (IR),73
2101,Insulin levels,73
3240,Serum insulin,73
2359,Markers of insulin metabolism,73
2102,Insulin metabolism markers,73
2104,Insulin sensitivity,73
1931,Homeostatic model of assessment for insulin resistance (HOMA-IR),73
1929,Homeostasis model of assessment-estimated insulin resistance (HOMA-IR),73
4220,insulin,73
1197,Connected speech,74
3292,Speech rate,74
3749,Voice,74
3290,Speech Tempo,74
3294,Speech timing,74
4505,speech production,74
4506,speech rate,74
3268,Slower speech rate,74
4507,speech timing,74
3289,Speech,74
2043,Iba1,75
1964,IBA-1,75
3152,SICI,75
4486,sICAM-1,75
2042,Iba-1,75
3250,Single-key tapping test,76
85,BRAIN tap test,76
343,Alternate-key tapping test,76
3386,TAS Test single-key tapping,76
4543,tapping frequency,76
3501,Tapping speed,76
4544,tapping variability,76
1585,Finger-Tapping Test,76
3813,Wisconsin Card Sorting Test,77
3109,Rivermead Behavioural Memory Test (RBMT),77
1628,Free and Cued Selective Reminding Test (FCSRT),77
2386,Memory Alteration Test (M@T),77
1203,Cookie Theft descriptions,77
215,APOE4-R251G,78
3933,apoE3-V236E,78
3932,apoE3-R136S,78
210,APOE3-Jacksonville (APOE3-Jac),78
209,APOE3-Christchurch (APOE3-Ch),78
219,APOε4 carriers,78
3936,apoe4 carrier status,78
200,APOE ε4 allele carriers,78
211,APOE3-R145C,78
376,Amylin (IAPP),79
1383,Drebrin,79
4518,substantia nigra (SN),79
2648,Optineurin,79
2605,Nicastrin,79
2609,Nilotinib,79
2612,Nitrite,79
2121,Irisin,79
2196,Latency to reach the platform,80
2195,Latency to reach new platform,80
1034,CentPT latencies,80
2197,Latency to target,80
2493,N200 latency,80
2699,P3b latency,80
2693,P300 latency,80
2692,P300 amplitude and latency,80
1996,IL-18,81
2002,IL-2,81
2007,IL-6,81
2003,IL-22,81
1983,IL-10,81
1982,IL-1,81
2008,IL-7,81
2009,IL-8,81
2011,IL12,81
2013,IL17,81
1992,IL-17,81
1993,IL-17A,81
1995,IL-17α,81
1990,IL-15,81
2020,IL6,81
2004,IL-3,81
2019,IL2,81
1994,IL-17F,81
1991,IL-16,81
2006,IL-5,81
1999,IL-1b,81
1984,IL-12,81
2061,Il6,81
1997,IL-1R4,81
1989,IL-13,81
1998,IL-1RA,81
2005,IL-4,81
1985,IL-12:IL-23p40,81
791,Brain age,82
801,Brain water content,82
2455,Modular organization of the brain,82
802,Brain-age gap,82
3975,brain network characteristics,82
806,BrainAGE score,82
1797,Graph theory-based brain network changes,82
3974,brain morphology,82
805,BrainAGE,82
985,CST7,83
1236,Cst7,83
2707,PALT,83
861,CCT,83
98,CSE,83
903,CDT,83
953,CPT,83
945,COMT,83
818,C-TMT-A,84
3137,SDMT,84
819,C-TMT-B,84
3423,TMT,84
3014,RBMT,84
3425,TMT B,84
86,BVMT-R,84
3429,TMTB,84
3427,TMT-A (s),84
3426,TMT-A,84
3424,TMT A,84
3428,TMT-B,84
2497,NAD+ levels,85
2233,Liver enzyme elevations,85
4415,pharmacogenomic characteristics,85
3892,aminotransferase elevations,85
578,Aβ-degrading enzymes,85
2099,Insulin degrading enzyme,85
4168,genetic variations in drug metabolism enzymes,85
4070,cleaved caspase-3,86
408,cleaved-caspase 3,86
848,CASP4,86
3989,caspase pathways,86
1132,Cleaved caspase 3,86
1133,Cleaved caspase-3,86
303,Activated Caspase 3,86
1015,Caspase 3,86
847,CASI,86
415,Amyloid peptide,8
401,Amyloid beta peptides,8
402,Amyloid beta peptides (Aβ),8
381,Amyloid Beta Peptides Burden,8
400,Amyloid beta (Aβ) peptides,8
533,Aβ (amyloid beta peptides),8
4437,plasma amyloid-β (Aβ) peptides,8
406,Amyloid beta peptides42,8
404,Amyloid beta peptides (abeta 40 and 42),8
616,Aβ40 peptide,8
653,Aβx–40 peptide levels,8
448,Amyloid-β peptide (Aβ),8
3901,amyloid beta peptides,8
3902,amyloid beta peptides accumulation,8
427,Amyloid β peptide (Aβ),8
559,Aβ peptide,8
3903,amyloid beta peptides burden,8
435,Amyloid-beta (Aβ) peptides,8
3906,amyloid peptides,8
405,Amyloid beta peptides40,8
544,Aβ amyloid beta peptides,8
560,Aβ peptides,8
3961,beta-amyloid1–42 peptide,8
2063,Imidazoline-2 binding sites,88
1829,HIF-1α,88
340,Alpha-2 macroglobulin,88
4112,eIF2α,88
1464,Endothelin-1 (EDN1),88
2477,Myelin proteins,88
3809,White matter volume,89
4603,white matter hyperintensities,89
3807,White matter lesion volume,89
4604,white matter hyperintensity (WMH) volume,89
3792,White Matter Hyperintensity Volume (WMH Volume),89
3793,White Matter Hyperintensity Volume (WMHV),89
3804,White matter hyperintensity volumetry,89
3796,White matter hyperintensities,89
3797,White matter hyperintensities (WMH),89
3803,White matter hyperintensity volume (WMHV),89
3801,White matter hyperintensity (WMH) volume,89
3800,White matter hyperintensities (WMHs),89
3790,White Matter Hyperintensities (WMH),89
3791,White Matter Hyperintensities (WMHs),89
1221,Cortical thickness in inferior temporal gyri,90
1659,Fusiform gyrus thickness,90
1332,Dentate gyrus (DG) volume,90
2078,Inferior parietal gyrus cortical thickness,90
1222,Cortical thickness in temporal gyri,90
1333,Dentate gyrus volume,90
3947,balance function,91
2929,Posture and Balance,91
2650,Orientation,91
720,Balance,91
3946,balance,91
3225,Semantic Paraphasia,92
3577,TorCA Subscores,92
2832,Phonemic paraphasia,92
1925,Hirano bodies,92
4079,composite-cerebellum SUVR,93
3269,Small intraventricular mass,93
2873,Pituitary mass,93
1044,Cerebellar hemispheric mass,93
2198,Left Cerebellum,93
3995,cerebellum,93
3463,TT aglycones,94
4584,ttau,94
3500,Talk testing (TT),94
4538,tTau,94
3465,TTs,94
3462,TT (Tinetti Test),94
3461,TT,94
4539,tTau levels,40
3464,TTR,94
4132,fALFF,95
4136,fasudil hydrochloride,95
1510,FAQ scores,95
4239,left precuneus fALFF,95
1503,FA,95
1578,Fasudil,95
1509,FAQ,95
1505,FA-rate,95
2403,Methionine,96
2384,Memantine,96
4270,memantine,96
2402,Metformin,96
4594,velocity,97
3783,Walking speed,97
4601,walking speed,97
4460,pulse wave velocity,97
3352,Swimming speed,97
1094,Cerebral spinal fluid t-tau,98
1093,Cerebral spinal fluid p-tau,98
1089,Cerebral spinal fluid Total tau,98
1088,Cerebral spinal fluid Phospho-tau,98
1087,Cerebral spinal fluid N-p-tau217,98
1086,Cerebral spinal fluid N-p-tau181,98
1085,Cerebral spinal fluid Mid-p-tau231,98
4055,cerebral spinal fluid total tau,98
4052,cerebral spinal fluid tau,98
4057,cerebral spinal fluid total-Tau,98
4043,cerebral spinal fluid p‐tau181,98
4019,cerebral spinal fluid Mid‐p‐tau231,98
4044,cerebral spinal fluid p‐tau217,98
4024,cerebral spinal fluid P-tau,98
4045,cerebral spinal fluid p‐tau231,98
4042,cerebral spinal fluid p‐tau,98
4040,cerebral spinal fluid phosphorylated tau (p-tau),98
4039,cerebral spinal fluid phosphorylated tau (P-tau),98
4023,cerebral spinal fluid N‐p‐tau181,98
4037,cerebral spinal fluid phospho-Tau,98
4038,cerebral spinal fluid phosphorylated tau,98
4035,cerebral spinal fluid p-tau181,98
4034,cerebral spinal fluid p-tau,98
4050,cerebral spinal fluid t-tau,98
4028,cerebral spinal fluid T-tau,98
4025,cerebral spinal fluid P-tau217,98
4036,cerebral spinal fluid p-tau181 levels,98
4056,cerebral spinal fluid total tau (T-tau),98
4388,p62/SQSTM1,99
3877,[62Cu]ATSM,99
3879,[¹⁸F]FEBU,99
4349,p-H2A.X Ser139,99
3758,WHOdas 2.0,99
2253,MAN2A1,99
3123,SASP factors,99
2743,PGRN mutation carriers,100
224,APP gene,100
227,APP mRNA,100
95,A673T mutation in APP,100
228,APP mutation,100
225,APP gene mutation,100
1202,Controlled Oral Word Association Test (COWAT),101
3723,Verbal fluency,101
387,Verbal Fluency (animal names),101
3724,Verbal fluency difficulties,101
385,Verbal Fluency,101
389,Verbal Fluency—Animals,101
388,Verbal Fluency test,101
2217,Letter (FAS) and Category Verbal Fluency,101
3721,Verbal Performance (number of animals recited),101
386,Verbal Fluency (VF) tests,101
2218,Letter fluency,101
3725,Verbal fluency test,101
1632,Frontal Assessment Battery (FAB),102
1631,Frontal Assessment Battery,102
3067,Repeatable Battery for the Assessment of Neuropsychological Status (RBANS),102
1633,Frontal Assessment Battery (FAB) score,102
1637,Frontal lobe function (FAB score),102
3245,Severe Impairment Battery (SIB),102
2591,Neuropsychological Test Battery (NTB),102
908,CERAD battery of mental status tests,102
3478,TUGdt MB months/10 s,103
3479,TUGdt MB number of months,103
3481,"TUGdt MB, months/10 s",103
4314,months/10 s,103
3482,"TUGdt MB, number of months",103
4313,months/10s,103
1731,Gamified cognitive tasks,104
1165,Cognitive function,104
1767,Global cognition,104
4159,functional skills,104
1157,Cognition,104
3285,Spatial abilities,104
4074,cognitive function,104
1335,Design Fluency,104
4347,ozagrel sodium,105
368,Ammonia,105
2909,Plasma kallikrein,105
747,Bexarotene,105
4503,sodium benzoate,105
4100,dipeptides,105
3273,Sodium,105
2830,Phenylalanine,105
4572,theobromine,105
2829,Phenserine,105
2969,Pseudoflavonifractor,105
132,ADAS-Cog-11,106
128,ADAS-Cog 13,106
124,ADAS,106
140,ADAS-cog12,106
139,ADAS-cog11,106
127,ADAS-Cog 11,106
138,ADAS-cog-13,106
125,ADAS-Cog,106
136,ADAS-cog,106
142,ADAScog11,106
141,ADAS-mem,106
313,Adalimumab,106
135,ADAS-Cog14,106
133,ADAS-Cog11,106
3628,Traumatic Brain Injury (TBI),107
3323,Stroke,107
1102,Cerebrovascular disease,107
929,CLQT Composite Severity,107
3324,Stroke lesion volume,107
4003,cerebral small vessel disease (CSVD),107
248,ASV_19,108
183,GV1001,108
249,ASV_9,108
182,GV-98,108
1689,GM-CSF,108
2277,MEV,108
1690,GMV,108
3660,UFOV,108
1981,IIV,108
2698,P3b amplitude,109
2673,P1 amplitude,109
2274,MEP amplitude,109
2275,MEP amplitudes,109
1439,ERN (Error-related negativity) amplitude,109
2691,P300 amplitude,109
2688,P3 amplitude,109
2696,P3a amplitude,109
2490,N100 amplitude,109
2492,N200 amplitude,109
2487,N1 amplitude,109
3037,RPTOR,110
814,Butyrate,110
846,CANTAB-RVP,110
497,Arc,110
3986,cadence,110
1488,Etanercept,110
1550,FMQ,111
825,C1qb,111
78,73Q,111
1154,CoQ10,111
824,C1q,111
2510,NFQ,111
47,23Q,111
68,48Q,111
2545,NQ01,111
43,18Q,111
2772,PQ912,111
4254,mI/Cr,112
959,CRP levels,112
955,CR1,112
961,CRT latencies,112
958,CRP,112
960,CRT,112
1115,Cho/Cr,112
4205,hs-CRP,112
956,CR3,112
3495,TVPAC,113
4570,the mother,113
1260,DAD,113
1555,FR,113
88,A,113
1446,Education,113
458,the window,113
2259,MBA,113
1265,DAS,113
1939,Huntingtin,114
1153,Clusterin genotype,114
1152,Clusterin,114
3984,cAMP,114
2564,Nestin,114
3438,"TNF-α, IL-1β and IL-6",115
2113,Interleukin-2,115
2112,Interleukin-1 (IL-1),115
2001,IL-1β,115
4225,interleukin-6,115
2018,IL1β,115
2114,Interleukin-6,115
2115,Interleukin-6 (IL-6),115
3031,RNFL thickness,116
2620,Nrf2,116
2512,NGF,116
2546,NRF2,116
4264,mature NGF,116
3030,RNFL,116
2224,Life Experience Questionnaire (LEQ),117
1643,Functional Assessment Staging Scale (FAST),117
3218,Schedule for the Evaluation of Individual Quality of Life - Direct Weighing (SEIQoL-DW),117
309,Activities of Daily Living Questionnaire,117
2812,Patient Health Questionnaire (PHQ-9),117
1401,ECG/HRV,118
3075,Resting heart rate,118
1400,ECG,118
1869,Heart Rate Variability (HRV),118
188,Heart rate,118
3164,SMS,119
1862,Handwriting,119
3165,SMS consistency,119
3549,Text,119
76,67-kDa laminin receptor,120
2459,Monoamine oxidase B,120
4230,lamin B1,120
2254,MAO-B,120
455,Annexin A2,120
811,Bristol ADL,121
812,Bristol scores ADL,121
146,ADCS-ADL scores,121
155,ADNC scores,121
157,ADS score,121
144,ADCS ADL total score,121
61,30CST,122
89,A+T+ profile,122
90,A/T/N system,122
2475,Munc18c,122
1144,Clock C,122
1147,Clock T3111C,122
2365,Maximum plasticity (T5–30),123
2364,Maximum plasticity,123
2920,Plasticity T10,123
2261,MC mean plasticity,123
3376,T10 plasticity,123
3422,TMS-induced plasticity,123
3380,T5 plasticity,123
2922,Plasticity measures,123
2921,Plasticity T5,123
2372,Mean plasticity T5-T30,123
2260,MC max. plasticity,123
238,Mean plasticity (T5–30),123
1864,HbA1c,124
1865,HbA1c levels,124
4178,glycated hemoglobin,124
2661,Oxygenated hemoglobin (Oxy-Hb),124
1875,Hemoglobin,124
1876,Hemoglobin A1c (HbA1c),124
1874,Heme oxygenase 1 (HO-1),124
1796,Granulovacuolar degeneration,125
4181,granulovacuolar degeneration (GVD),125
1795,Granulocytes-to-lymphocytes ratio,125
1794,Granulocytes,125
1793,Granule cell layer thickness,125
1792,Granule cell layer cellularity,125
495,Appetite/eating abnormalities,126
498,Argyrophilic grain disease (AGD),126
3728,Verrucomicrobia,126
1815,Gut hormones,126
1130,Cirrhosis,126
2045,Idalopirdine,126
1870,Heart disease,126
520,Autophagy,126
845,CAMCOG,127
4493,sVCAM-1,127
844,CAM,127
3687,VILIP1,127
2725,PECAM1,127
3686,VILIP-1,127
813,Burst firing patterns,128
3088,Retroactive interference (RI) performance,128
782,Braak stages,128
1181,Communication Problems Scale,128
3354,Synapsin 1,129
4524,synaptopathy,129
3356,Synapthophysin,129
3360,Synaptophysin,129
3355,Synapsin-1,129
4526,synaptotagmin,129
4525,synaptophysin,129
3363,Synaptotagmin,129
3361,Synaptophysin expression,129
2804,Parietal activity,130
4095,daytime activity level,130
3886,activity count,130
310,Activity,130
311,Activity Levels,130
4094,daytime activity,130
3787,Whishaw index,131
723,Barthel Index,131
3344,Sum Index,131
1728,Gallagher index,131
3578,TorCA Sum Index,131
703,BI (Barthel Index),131
1229,Cortisol levels,132
1227,Cortisol,132
3211,Salivary cortisol,132
1228,Cortisol (COR),132
1230,Cortisolism,132
4495,salivary cortisol,132
4088,cortisol,132
3313,Stress and cortisol,132
3092,Rey Auditory Verbal Learning Test (RAVLT) total score,133
3722,Verbal expression and learning scores,133
1009,"California Verbal Learning Test-Second Edition, Adult Version (CVLT-II)",133
1189,Complutense Verbal Learning Test (TAVEC),133
3091,Rey Auditory Verbal Learning Test (RAVLT) delayed recall score,133
3089,Rey Auditory Verbal Learning Test,133
3090,Rey Auditory Verbal Learning Test (RAVLT),133
4241,leptin,134
4510,statin,134
3302,Statins,134
2215,Leptin,134
3662,ULK1,135
2672,P1,135
3497,TYK2,135
2635,OGG1,135
1588,Fis1,135
3023,RIPK1,135
3153,SIK1,135
2547,NRG1,135
1878,Hey1,135
3663,ULK2,135
707,BMAL1,135
2486,N1,135
3034,RPS6KA1,136
3035,RPS6KA2,136
3036,RPS6KB1,136
56,2DG6P,136
54,2DG,136
898,CDR-SB scores,137
891,CDR,137
892,CDR (global),137
893,CDR Sum of Boxes,137
894,CDR score,137
895,CDR total score,137
902,CDRS,137
900,CDR-Sb,137
896,CDR-SB,137
897,CDR-SB score,137
899,CDR-SOB,137
901,CDR-sb,137
2551,NTB,138
2143,K-BNT,138
2283,MGnD,138
1830,HKLLT,138
3016,RD,138
2347,MVGT,138
3880,aMT,138
2548,NRGN,138
3038,RT,138
2996,Qβ-induced T-cell responses,139
1447,Effector helper and cytotoxic T lymphocytes (CD28−),139
4611,α-syn-specific T cell reactivity,139
742,Beta cell function,139
2923,Platelets-to-lymphocytes ratio,139
1930,Homeostatic model assessment for B-cell function (HOMA-B),139
1042,Central memory helper T lymphocytes (CD45RA−CCR7+),139
4013,cerebral spinal fluid Aβ42/Aβ40,140
4010,cerebral spinal fluid Aβ42,140
1082,Cerebral spinal fluid Aβ42/40 ratio,140
1081,Cerebral spinal fluid Aβ42 measurement,140
1080,Cerebral spinal fluid Aβ42,140
1079,Cerebral spinal fluid Aβ40,140
1078,Cerebral spinal fluid Aβ(1–42) levels,140
1083,Cerebral spinal fluid Aβ42/Aβ40,140
1077,Cerebral spinal fluid Aβ levels,140
4009,cerebral spinal fluid Aβ1–42,140
4563,tau/cerebral spinal fluid Aβ42 ratios,140
4008,cerebral spinal fluid Aβ1–40,140
4007,cerebral spinal fluid Aβ,140
4049,cerebral spinal fluid t-Tau/Aβ42 ratio,140
4053,cerebral spinal fluid tau/Aβ42 ratio,140
1090,Cerebral spinal fluid amyloid-β 42 peptide (Aβ42),140
4051,cerebral spinal fluid t-tau/Aβ42 ratio,140
4029,cerebral spinal fluid amyloid (Aβ42),140
4247,lower cerebral spinal fluid Aβ42,140
4030,cerebral spinal fluid amyloid-β1–42,140
4015,cerebral spinal fluid Aβ42/t-tau,140
4014,cerebral spinal fluid Aβ42/p-tau,140
4012,cerebral spinal fluid Aβ42/40,140
4011,cerebral spinal fluid Aβ42 levels,140
3838,Zarit Burden Interview,141
2626,Number of revolutions,141
4311,modularity,141
178,AN-1792,141
1342,Dialister,141
479,ApoE4,142
476,ApoE-4,142
204,APOE-ɛ4,142
188,APOE,142
469,ApoE,142
474,ApoE ε4,142
482,ApoEε4,142
473,ApoE status,142
208,APOE3,142
3934,apoE4,142
194,APOE ɛ4,142
212,APOE4,142
195,APOE ε2,142
193,APOE status,142
216,APOEε4,142
3935,apoe4,142
203,APOE-4,142
206,APOE-ε4,142
191,APOE fragments,142
218,APOε4,142
207,APOE2,142
198,APOE ε4,142
189,APOE e4,142
1374,Dkk1,143
1255,D54D2,143
1292,DPs,143
1306,DYRK1A kinase activity,143
1305,DYRK1A,143
1287,DMS48,143
1284,DMN,143
179,AN1792,144
1969,IDE rs2251101,144
1443,EVP-0962,144
1394,E2609,144
2526,NNI-362,144
2499,NAP226-90,144
3659,UE2343,144
675,BAN2401,144
843,CAD106,144
4479,rs935840,144
841,CAB101,144
842,CAB102,144
4478,rs2143466,144
94,A673T,144
3378,T3D-959,144
2381,Mediterranean diet,145
2380,Mediterranean Diet Adherence,145
2627,Nutrition,145
1345,Diet (MIND diet),145
1881,High glycemic diet,145
1788,Glycemic control,145
4098,dietary changes,145
319,Aducanumab,146
184,ANU-ADRI total,146
3888,aducanumab,146
183,ANU-ADRI risk,146
3599,Total protein,147
3098,Ribosomal proteins,147
1114,Chitinase-3-like protein 1 (CHI3L1 or YKL-40),147
2966,Protein carbonyls,147
2965,Protein carbonyl content,147
3881,abnormal protein deposition,147
2964,Protein carbonyl,147
87,9.00E+04,148
835,C9orf72,148
833,"C99, C89, and C83",148
697,BEC96,148
696,BEC 96 Total,148
834,C9ORF72,148
4450,primacy/recency ratio,149
4167,generalization,149
1369,Discrimination learning,149
3055,Reduced primacy effects,149
2348,"Macrophage inflammatory protein-1α [MIP-1α, CCL3]",150
2286,MIP-1β [CCL4],150
2263,MCP-1,150
2264,MCP-1/CCL2,150
2265,MCS-B,150
2285,MIP-1α,150
3022,RICTOR,151
4411,parietal lobule,151
2182,LICI,151
3198,SUVRMNI-CB,151
3039,RUD-Lite,151
3979,brevican,151
3199,SUVRMNI-WM,151
3980,bumetanide,151
2980,QC inhibition,152
2087,Inhibition cost,152
2088,Inhibitory/Excitatory Intracortical Circuits,152
2979,QC activity,152
367,"Amino acids (phenylalanine, isoleucine, histidine)",153
505,Aspartate aminotransferase (AST),153
504,Aspartate Transaminase (AST),153
366,Amino acid levels,153
330,Alanine aminotransferase (ALT),153
329,Alanine Transaminase (ALT),153
4519,superficial parafoveal vessel density,154
4408,parafoveal and peripapillary densities,154
2396,Meningeal Lymphatic Vessels,154
4106,dura mater lymphatic vessels,154
4041,cerebral spinal fluid protein markers,155
4033,cerebral spinal fluid homovanillic acid (HVA),155
1091,Cerebral spinal fluid biomarkers,155
1092,Cerebral spinal fluid markers,155
1095,Cerebro-cerebral spinal fluid examination,155
4032,cerebral spinal fluid biomarkers,155
4031,cerebral spinal fluid biomarker,155
4047,cerebral spinal fluid sAPPβ,155
1076,Cerebral spinal fluid (CSF) tests,155
1084,Cerebral spinal fluid F2-IsoPs,155
1075,Cerebral spinal fluid (CSF) biomarkers,155
4046,cerebral spinal fluid sAPPα,155
1073,Cerebral spinal fluid,155
4027,cerebral spinal fluid SOM,155
4004,cerebral spinal fluid (CSF) cholinergic markers,155
4048,cerebral spinal fluid sVCAM-1 levels,155
4005,cerebral spinal fluid (CSF) clearance,155
4006,cerebral spinal fluid AD biomarkers,155
4026,cerebral spinal fluid S100B,155
3295,Spinal fluid measures,155
4022,cerebral spinal fluid NfL levels,155
4021,cerebral spinal fluid NSE,155
4020,cerebral spinal fluid NPY,155
4018,cerebral spinal fluid F2-isoprostane levels,155
1057,Cerebral Spinal Fluid (CSF) Influx,155
4016,cerebral spinal fluid BACE,155
1074,Cerebral spinal fluid (CSF),155
4054,cerebral spinal fluid total sAPP,155
4017,cerebral spinal fluid DJ-1,155
4058,cerebral spinal fluid tracer (FITC-Dextran-3kD),155
3447,TREM-2,156
3632,Trehalose,156
3450,TREM2 R47H,156
865,CD127low-neg Tregs,156
867,CD25high Tregs,156
3631,Tregs,156
3633,Trem2,156
3448,TREM1,156
3449,TREM2,156
874,CD39+ Tregs,156
3586,Total Recall (TR) scores,157
2705,PAL first trial memory score,157
1627,Free Recall (FR) scores,157
2240,Low memory scores,157
3883,acquisition z-scores,157
448,recall-ratio z-scores,157
1321,Delayed memory domain score,157
2068,Immediate memory domain score,157
2331,MRI-derived WMH,158
53,2D T2-weighted GRE MRI,158
1950,Hyperpolarized 129Xe MRI,158
52,2D T2-weighted FLAIR MRI,158
63,3D T1-weighted MRI,158
2334,MRI-derived total WMH,158
3287,Spatio-temporal analysis of walking (GAITRite),159
4163,gait variability,159
185,Gait,159
1672,GAITRite®,159
4161,gait,159
3573,Timed Gait Test,159
1720,"Gait variables (velocity, variability, frequency)",159
188,Gait characteristics,159
2617,Normalized Brain Volume (NBV),160
3593,Total brain volume (TBV),160
798,Brain volume,160
3592,Total brain volume,160
3976,brain volume,160
3334,Subcortical Volumes,160
1223,Cortical volume,160
3017,REGIONAL CEREBRAL VOLUME,160
3337,Subiculum volume,160
3580,Total Brain Volume (TBV),160
3811,Whole brain volume,160
2895,Plasma Mir107 expression,161
4295,microRNAs,161
4066,circRNAs,161
2409,MicroRNA-155 (miR155) and IFN-γ,161
4294,microRNA-130a,161
2896,Plasma Mir107 levels,161
1457,Electrophysiological response,162
4451,primary somatosensory cortex (PSC),162
2473,Motor-evoked potentials (MEPs),162
2614,Noradrenergic modulation,162
1584,Field excitatory postsynaptic potentials (EPSPs),162
2585,Neurophysiological measures,162
4114,eProt,163
1429,EPHA1,163
1397,EAAT2,163
1459,Emp1,163
1396,EAAT1,163
1393,E-Selectin,163
3962,beta1 rhythm,164
1129,Circadian Clocks Desynchronization,164
789,"Brain Rhythms (δ, θ, α1, α2, β1, β2, γ)",164
1226,Corticosteroid Circadian Rhythm,164
4067,circadian rhythms,164
3889,advanced glycation end products,165
4180,glymphatic system,165
3049,Receptor for advanced glycation end products,165
4179,glycine recognition sites (GlyRS),165
4188,higher strychnine-sensitive glycine receptor (GlyRS) functioning,165
1787,GlyRS functioning,165
1789,Glymphatic Exchange,165
611,Aβ28–42,166
614,Aβ40 and Aβ42,166
629,Aβ42/Aβ40 ratios,166
644,Aβ5-42,166
623,Aβ42/40 ratio,166
643,Aβ5-40,166
622,Aβ42/40,166
1454,Elecsys Aβ1–42,166
615,Aβ40 levels,166
620,Aβ42 levels,166
2168,LC-MS-Arc Aβ42/40,166
619,Aβ42,166
638,Aβ42EI/Aβ40EI,166
2027,IP-MS-WashU Aβ42/40,166
618,Aβ40/Aβ42,166
642,Aβ43,166
617,Aβ40 ratio,166
645,Aβ5-X,166
1959,IA-Elc Aβ42/40,166
626,Aβ42/Aβ40,166
637,Aβ42EI,166
625,Aβ42/Aβ38 ratio,166
627,Aβ42/Aβ40 ratio,166
600,Aβ11-42,166
610,Aβ22-28,166
601,Aβ18–35,166
647,AβX–38,166
652,Aβx-42,166
612,Aβ38,166
624,Aβ42/Aβ38,166
538,Aβ 42/40,166
648,AβX–42,166
650,"Aβx-38, Aβx-40, and Aβx-42",166
613,Aβ40,166
651,Aβx-40,166
639,Aβ42IT,166
3050,Recognition Accuracy (Recog),167
2482,N-gram features,167
2290,MLU (Mean Length of Utterance),167
297,Acoustic features,167
2808,Part-Of-Speech cross-entropy,167
4323,n-gram features,167
4508,speech-based classifiers,167
4577,total semantic units,167
1460,"Encoding, Storage and Recuperation (ESR) word list",167
4569,temporal speech features,167
3069,Rest durations,168
3652,Turn duration,168
3885,active minutes,168
3047,Reaction time (RT),168
3375,T1 relaxation time,168
1737,Gap duration,168
3046,Reaction Times,168
4107,dwell time,168
2116,Interpausal unit duration,168
305,Active durations,168
4078,completion time,168
2344,MTL subregions (DG/CA1),169
2343,MTL network flexibility,169
2204,Left MTG,169
2346,MTP,169
2342,MTL density and volume,169
2341,MTHFR,169
2158,L MTG,169
2340,MTG,169
143,ADCOMS,170
121,AD8,170
116,AD,170
122,AD8-slefd,170
698,BEHAVE-AD,170
119,AD-GRS,170
2988,QoL-AD,170
2983,QOL-AD,170
156,ADRD,170
910,CERAD score,18
912,CES-D scale,18
911,CES-D,18
1043,Cereb,18
904,CE,18
1033,Ceftriaxone,18
909,CERAD neuritic plaque score,18
907,CERAD Word List,18
906,CERAD,18
2209,Left frontal parietal network,172
1641,Frontostriatal circuit structural integrity,172
1640,Frontostriatal circuit functional connectivity,172
4153,frontostriatal structural connectivity,172
3103,Right frontal parietal network,172
2252,MAG:PLP1 ratio,173
2758,PLD3,173
2757,PLAS,173
2243,Lp-PLA2,173
2874,PlGF,173
2875,PlGF and Tie-2,173
2251,MAG:PLP1,173
1368,Discourse difficulties,174
3720,Verbal Intrusions,174
1329,Delusions,174
946,CONSCIENTIOUSNESS,174
298,Psychoaffective Factors,174
1858,Hallucinations,174
1370,Disinhibition,174
1645,Functional Connectivity (FC),175
4155,functional connectivity (FC),175
1648,Functional connectivity,175
1654,Functional connectivity (PLV),175
1644,Functional Connectivity,175
1649,Functional connectivity (FC),175
1650,Functional connectivity (FC) in the left precuneus,175
1651,Functional connectivity (FC) in the precuneus and temporal gyrus,175
1652,Functional connectivity (FC) in the temporal gyrus,175
1653,Functional connectivity (FC-values),175
4154,functional connectivity,175
251,AT profile,176
256,ATF4,176
255,ATF3,176
250,AT,176
252,AT8,176
2016,IL1B rs16944,177
2015,IL1B rs1143627,177
2014,IL1B,177
2059,Il1a,177
2060,Il1b,177
2017,IL1α,177
2000,IL-1α,177
3665,UPDRS III,178
3667,UPSA,178
3666,UPDRS assessments,178
3411,THFs/THE ratio,179
1500,F/B ratio,179
3565,Theta/Beta ratio (TBR),179
4322,n-6/n-3 ratio,179
1877,Hesitation Ratio,179
1587,Firmicutes/Bacteroidetes (F/B) ratio,179
3552,Th1/Th2 ratio,179
3675,VAT/SAT ratio,179
3859,[18F]FDG,180
3851,[18F]-FDG,180
3861,[18F]GSK2647544,180
3868,[18F]THK-5351,180
3854,[18F]2B-SRF101,180
3867,[18F]ROStrace,180
3855,[18F]AZD4694,180
3866,[18F]RO948,180
3876,[18F]ox-ROStrace,180
3864,[18F]GTP1 tau PET,180
3856,[18F]BR-351,180
3863,[18F]GTP1 SUVR,180
3858,[18F]FBAT,180
3857,[18F]BR-420,180
3862,[18F]GTP1,180
3865,[18F]MK-6240,180
18,18F-DPA-84,180
4182,graphic markers,181
4599,vocal markers,181
1445,Early AD markers,181
2811,Passive Digital Marker (PDM),181
375,Amygdale atrophy,182
374,Amygdalar volume,182
3894,amygdalar volume,182
1896,Hippocampal and amygdalar volume,182
373,Amygdala volume,182
3893,amygdala,182
372,Amygdala,182
3645,TrkB,183
3122,SAPK/JNK,183
2756,PKB,183
694,BDNF/TrkB,183
3209,SYK,183
785,Brain Atrophy,184
793,Brain atrophy rates,184
792,Brain atrophy,184
3591,Total brain atrophy rates,184
1634,Frontal Cortex Atrophy,184
512,Atrophy in Temporal and Parietal Cortices,184
1049,Cerebral Atrophy,184
1059,Cerebral atrophy,184
3969,brain atrophy,184
3335,Subcortical atrophy,184
3970,brain atrophy profiles,184
2943,Prefrontal cortex atrophy,184
398,brain atrophy rate,184
1214,Cortical atrophy,184
3061,Regional brain atrophy rates,184
4081,cortical and limbic atrophy,184
780,Boston Naming Test (BNT),185
779,Boston Naming Test,185
2552,Naming Disorders,185
2640,Object naming test,185
285,Acetate,186
2957,Propionibacterium acnes (P. acnes),186
286,Acetic acid,186
2959,Propionyl-CoA carboxylase,186
2481,N-acetylaspartate (NAA),186
3133,"SCFAs (butyrate, acetate, propionate)",186
3131,SCFA (Short Chain Fatty Acids),186
993,CX3CR1,187
994,CXCL10,187
1615,Fornix,187
4485,sCTX,187
1240,Cx43,187
920,CGIC,187
919,CGI-I,187
918,CGDS-SF,187
2817,Per2 G,188
2816,Per1,188
2728,PER1,188
2729,PER2,188
2730,PER2 C111G,188
2731,PER2 C111G polymorphism,188
2732,PER2 G allele,188
1662,G Allele,188
2733,PER2 genotype,188
3939,apolipoprotein E (ApoE) genotype,189
484,Apolipoprotein 4,189
485,Apolipoprotein C 2 (APOC2),189
486,Apolipoprotein E (APOE),189
487,Apolipoprotein E (APOE) ε4,189
488,Apolipoprotein E (APOE) ε4 allele,189
489,Apolipoprotein E (ApoE) ε4,189
490,Apolipoprotein E (ApoE) ε4 allele,189
493,Apolipoprotein E ε4 (APOE4),189
492,Apolipoprotein E genotyping,189
3938,apolipoprotein B (apo B),189
3940,apolipoprotein E epsilon 4 allele,189
491,Apolipoprotein E genotype,189
3930,apo B lipoproteins,189
3298,Src,190
3189,SRT latency,190
3188,SRT latencies,190
3186,SRSS,190
3187,SRT,190
1625,Fractional anisotropy (FA) in cholinergic pathways,191
1124,Cholinesterase activity,191
4063,cholinergic pathways,191
1123,Cholinergic system,191
1122,Cholinergic neurons,191
1121,Cholinergic activity,191
3596,Total cholinesterase (TChE),191
1120,Choline acetyltransferase (ChAT),191
4064,cholinesterase inhibitors,191
3927,anticholinergic burden,191
3945,bFGF,192
728,Basic fibroblast growth factor [BFGF],192
1544,FGF-2,192
1545,FGF9,192
1273,DELAPAGTGVSREAVSG,193
1002,Ca2+,193
851,CAW,193
1003,CaV1.2,193
1027,Cav1,193
850,CAVIRE,193
840,CAA,193
1004,CaV1.3,193
872,CD39,194
881,CD47,194
885,CD8,194
882,CD59,194
1029,Cd14,194
864,CD11c,194
866,CD163,194
1030,Cd44,194
883,CD63,194
2130,Itgax (CD11c),194
875,CD4,194
1031,Cd9,194
863,CD11b,194
870,CD31,194
862,CD-11b,194
88,CD33,194
884,CD68,194
2458,Mono-CQAs,195
2457,Mono- and di-CQAs,195
954,CQAs,195
1337,Di-CQAs,195
1126,Cingulum bundle disruption,196
1128,Cingulum_Mid_R (aal),196
1127,Cingulum_Mid_R,196
1125,Cingulum bundle,196
4085,cortical thickness in parietal lobe,197
4084,cortical thickness in medial temporal lobe (MTL),197
3540,Temporal meta-ROI cortical thickness,197
4083,cortical thickness,197
4567,temporal meta-regions of interest (ROI) cortical thickness,197
2937,Precuneus thickness,197
1211,Cortical Thickness,197
2936,Precuneus cortical thickness,197
4086,cortical thickness in temporal lobe,197
2935,Precuneus cortex thickness,197
1218,Cortical thickness,197
2821,Pericalcarine cortical thickness,197
1635,Frontal Cortical Thickness,197
4151,frontal cortical thickness,197
1219,Cortical thickness in early regions,197
1212,Cortical Thickness (CT),197
2093,Insular cortical thickness,197
2163,L-type voltage sensitive Ca2+ channels (L-VSCCs),198
2161,L-VSCCs,198
2160,L-VSCC activity,198
2159,L-VSCC,198
3399,TDP-43-A,199
3398,TDP-43 pathology biomarkers,199
3397,TDP-43 (Transactive response DNA-binding protein 43 kDa),199
3396,TDP-43,199
1812,Growth associated protein 43,199
1575,Fasting insulin levels,200
1572,Fasting blood glucose,200
158,Fasting Insulin Levels,200
1576,Fasting plasma glucose,200
1577,Fasting plasma glucose (FPG),200
1574,Fasting insulin,200
1570,Fasting Glucose,200
1573,Fasting glucose,200
4135,fasting insulin,200
3575,Tmem66,201
3421,TMEM119,201
3377,T3,201
4537,tPA,201
3379,T4,201
3403,TG,201
3420,TMAO,201
4224,insulin/IGF signaling,202
508,Astrocytic insulin,202
2103,Insulin receptor signaling pathway (IRSP) genes,202
2105,Insulin signaling,202
509,Astrocytic insulin signalling,202
2561,Nerve Growth Factor (NGF),203
2877,Placental growth factor [PIGF],203
2876,Placental growth factor,203
2562,Nerve growth factor (NGF),203
3136,SDI,204
83,BPSD,204
3138,SDST,204
3026,RMSSD,204
3139,SDT,204
1702,GSH-peroxidase,205
3598,Total glutathione (GSH),205
3583,Total Glutathione (GSH),205
1782,Glutathione,205
1783,Glutathione (GSH),205
1784,Glutathione peroxidase (GSH-Px),205
1785,Glutathione peroxidase activity,205
2787,PSQI,206
2784,PSEN2,206
280,PC1,206
2775,PS1,206
2778,PS2,206
2781,PSEN1,206
2779,PSD95,206
2780,PSEN,206
748,Bielschowsky,207
754,Bilophila,207
749,Bielschowsky silver,207
702,BI,207
750,Bielschowsky silver stain,207
4461,pupil dilation,208
2973,Pupil dilation,208
1738,Gaze direction,208
1499,Eye gaze detection test,208
1498,Eye Movement,208
296,Acid phosphatase,209
2839,Phospholipase A2 (PLA2) activity,209
494,Apoptosis regulation,209
3884,activation of mitochondrial apoptosis,209
2656,Oxidative phosphorylation,209
3559,Theta Power,210
3564,Theta power,210
3563,Theta oscillations,210
3562,Theta frequency band,210
3561,Theta band power,210
4152,frontal-posterior theta coherence,210
3560,Theta band oscillations,210
4301,midline frontal theta power,210
4573,theta rhythm,210
2074,Increased theta-band power,210
369,Ampicillin,211
2950,Probiotics,211
3155,SLAB51 probiotic formulation,211
460,Antibiotics,211
931,CMAI,212
932,CMAI score,212
934,CMBs,212
935,CMMSE,212
937,CMRgl,212
938,CMRglc,212
939,CMV pp65 response,212
2803,Parietal CMBs,212
933,CMB,212
3532,Taurine,213
4545,tau,213
3387,TAUdown,213
3508,Tau PET,213
4529,t-Tau,213
3529,Tau-PET,213
3504,Tau (MAPT),213
3374,T-tau,213
4532,t-tau,213
3372,T-Tau,213
4558,tau-PET,213
4150,foetal tau,213
2739,PET-quantified tau,213
4564,taurine levels,213
4586,t‐tau,213
3388,TAUup,213
3503,Tau,213
4483,sAPPα,214
4576,total sAPP,214
3600,Total sAPP,214
4630,β-sAPP,214
4480,sAPP,214
3121,SAP102,214
3120,SAP,214
4609,α-sAPP,214
4481,sAPP-α,214
4484,sAPPβ,214
4482,sAPP-β,214
3128,SCD (Subjective Cognitive Decline),215
3338,Subjective Cognitive Decline (SCD),215
84,BPSD (Behavioral and Psychological Symptoms of Dementia),215
735,Behavioural and Psychological Symptoms of dementia (BPSD),215
3519,Tau pathology,40
3926,anti-tau antibodies,40
382,Amyloid Beta Peptides and Phosphorylated Tau,8
4580,total tau protein,40
4363,p-tau pathology,40
3525,Tau protein,40
398,Amyloid and tau,8
3527,Tau proteins,40
4555,tau proteins,40
4549,tau pathology,40
976,CSF amyloid and tau biomarkers,8
3510,Tau Protein,40
4546,tau biomarkers,40
3509,Tau PET pathology,40
3605,Total tau protein,40
4553,tau protein,40
2222,Lexical features,217
2228,Linguistic features,217
3366,Syntactic features,217
2221,Lexical components,217
3365,Syntactic components,217
3364,Syntactic complexity,217
3056,Reduced syntactic complexity,217
4499,sensor-based Frailty Measurement (FM),218
1360,Digital biomarkers (micro hand gestures from accelerometer data),218
4432,physiological micro tremors (7–8 Hz amplitude),218
1359,"Digital biomarkers (e.g., Neuro-Motor Index (NMI))",218
280,Aberrant motor activity,218
3003,RAP1B,219
2309,MRC1,219
990,CTNNB1,219
3390,TBC1D4,219
2474,Mtss1L,219
4258,mTORC1,219
849,CASS4,219
3231,Sensory impairment,220
517,Auditory cortex,220
518,Auditory network,220
2070,Impaired sound perception and recognition,220
2069,Impaired Auditory and Written Comprehension,220
2065,Immediate Recall,221
2393,Memory—Delayed Recall,221
3007,RAVLT delayed recall,221
2064,Immediate Memory Recall (MIR),221
1322,Delayed recall,221
2067,Immediate memory,221
2066,Immediate Recall (IR),221
1320,Delayed memory,221
1319,Delayed Verbal and Visual Recall,221
1318,Delayed Recall (DR),221
1317,Delayed Recall,221
1316,Delayed Memory Recall (MDR),221
2394,Memory—Delayed Recognition,221
2395,Memory—Immediate Recall,221
321,Affitope AD02,222
96,AAB-003,222
108,ACC-001,222
107,ACC,222
99,AADvac1,222
174,ALZ-801,222
98,AADvac-1,222
97,AAB-003 levels,222
2147,KU complex (Ku70 and Ku80),223
2154,Kir6.2,223
2153,Ki-67,223
2930,Potassium,223
4228,k3,223
3044,Radial Diffusivity (DR),224
117,AD (Axial Diffusivity),224
523,Axial Diffusivity (AD),224
525,Axial diffusivity (AD),224
524,Axial Diffusivity (AxD),224
522,AxD (axial diffusivity),224
3045,Radial Diffusivity (RD),224
3085,Retinoic acid receptors (RARs),225
14,13-cis-retinoic acid,225
3087,Retinol,225
3084,Retinoic Acid (RA),225
334,All-trans-retinoic acid (RA),225
3086,Retinoids,225
1703,GSH/GSSH,226
1701,GSH-Px,226
1700,GSH-PX,226
1699,GSH,226
181,GSSH,226
1977,IGF-1 receptor,227
1976,IGF-1,227
1979,IGF1,227
2100,Insulin growth factor 1 (IGF-1),227
1980,IGF1R,227
2106,Insulin-like Growth Factor 1 (IGF1),227
1978,IGF-I,227
4222,insulin-like growth factor 1 (IGF-1),227
4223,insulin-like growth factor-1 (IGF-1),227
1301,DTI,228
1348,Diffusion tensor imaging (DTI),228
1303,DTI measures,228
3765,WM diffusion metrics,228
1302,DTI and GM volume measures,228
4410,parahippocampal gyrus,229
4198,hippocampus,229
1889,Hippocampal GM density,229
4193,hippocampal binding memory task,229
1923,Hippocampus_L,229
1924,Hippocampus_L (aal),229
1895,Hippocampal activity,229
1894,Hippocampal activation,229
4196,hippocampal-sparing AD,229
1891,Hippocampal Synaptic Immunoreactivity,229
1903,Hippocampal size,229
1890,Hippocampal Occupancy (HOC),229
4251,mALFF values in the left hippocampus,229
1656,Functional connectivity of hippocampus,229
4201,"hippocampus, ventro-medial prefrontal, fronto-insular, and lateral temporal cortex",229
1913,Hippocampus,229
48,24HC,230
3836,ZDHHC21 p.T209S mutation,230
3835,ZDHHC21,230
2878,Plasma 24HC,230
2919,Plasma vitamin B12,231
3743,Vitamin B12,231
3742,Vitamin B-12,231
659,B1N1,231
658,B12,231
657,B1 cells,231
656,B cells,231
655,B Vitamins,231
4209,hyperproduction of reactive oxygen species,232
3048,Reactive Oxygen Species,232
2660,Oxygen blood level,232
3351,Sweating level,232
3994,cellular oxygen consumption rate (OCR),232
1551,FNDC5,233
2513,NIC5-15,233
3664,UNC5C,233
1565,Fabp5,233
180,ANAPC5,233
2024,INPP5D,233
1032,Cdh5,233
889,CDK5,233
832,C5,233
786,Brain Derived Neurotrophic Factor (BDNF),234
3978,brain-derived neurotrophic factor (BDNF),234
803,Brain-derived neurotrophic factor,234
804,Brain-derived neurotrophic factor (BDNF),234
3977,brain-derived neurotrophic factor,234
3972,brain derived neurotrophic factor (BDNF),234
2592,Neurotrophic Factors,234
2594,Neurotropic factors,234
239,AR global telemetry variance,235
240,AR object place and find telemetry variance,235
241,AR object placement fast Fourier transform (FFT),235
1658,Fusiform (% TIV),236
1914,Hippocampus (% TIV),236
794,Brain free fraction (fND),236
3810,Whole brain (% TIV),236
82,BPF (Brain Parenchymal Fraction),236
1025,Caudate and putamen volume,237
1026,Caudate volume loss,237
1023,Caudate,237
1024,Caudate Volume,237
1432,EQ-5D-3L,238
1433,EQ-5D-3L proxy,238
1434,EQ-5D-5L,238
2897,Plasma N-p-tau181,239
2898,Plasma N-terminal p-tau181,239
2900,Plasma P-tau217,239
2914,Plasma p-tau231,239
2913,Plasma p-tau217,239
2912,Plasma p-tau181,239
2917,Plasma tau,239
4436,plasma P-tau217,239
4440,plasma p-tau181,239
4369,p-tau181 (plasma),239
4441,plasma p-tau217,239
4443,plasma p‐tau181,239
4444,plasma tau,239
4442,plasma p-tau231,239
2633,ODI,240
1932,Homer 1,240
1933,Homer-1,240
2276,METs,240
4210,hypocretin-1,241
731,Beclin-1,241
1955,Hypocretin-1,241
4090,cyclin D1,241
1462,Endostatin,242
4121,endostatin,242
3280,Somatostatin,242
3281,Somatostatin (SOM),242
1657,Functional near-infrared spectroscopy (fNIRS),243
4134,fNIRS,243
2030,IR,243
2031,IR index,243
346,Aluminum,244
347,Aluminum (Al) concentration,244
349,Aluminum levels,244
1204,Copper,244
348,Aluminum concentration,244
3413,THK-5351 uptake,245
3412,THK-5351 PET,245
3414,THK5351,245
4386,p53,245
3163,SMB53,245
4514,stride length variability,246
3322,Stride width variability,246
4516,stride width,246
4517,stride width variability,246
3314,Stride Length,246
4513,stride length,246
2373,Mean stride time,246
3316,Stride length,246
4515,stride time variability,246
3317,Stride time,246
3318,Stride time variability,246
3321,Stride variability,246
1607,Fluorescein-conjugated dextran,247
3547,Texas Red-Dextran-70kD,247
3548,Texas Red–dextran,247
3709,Vascular endothelial growth factor [VEGF],248
1463,Endothelial function,248
3704,Vascular Endothelial Growth Factor (VEGF),248
3708,Vascular endothelial growth factor (VEGF),248
4139,flavonoids,249
3748,"Vitamin E, selenium",249
4607,α-Tocopherol (AT),249
3747,Vitamin E (α-tocopherol),249
3076,Resveratrol,249
2644,Olive oil,249
2503,NEK6,250
2559,Neprilysin,250
2560,Neprilysin (NPE),250
2502,NEFA,250
2565,NeuN,250
3325,Stroop Color-Word Interference Test,251
3328,Stroop incongruent words test,251
3327,Stroop Color-Word test,251
3326,Stroop Color-Word Test,251
3329,Stroop test,251
3330,Stroop test performance,251
3331,Stroop trial 3,251
500,Arterial Spin Labelling (ASL),252
499,Arterial Pulsatility,252
3941,arterial stiffness,252
380,"Vascular risk factors (e.g., smoking, obesity, diabetes)",252
3882,acetylcholinesterase,253
294,Acetylcholinesterase inhibitors,253
293,Acetylcholinesterase ([11C]PMP) PET,253
288,Acetylcholine (ACh),253
292,Acetylcholinesterase (AChE) activity,253
291,Acetylcholinesterase (AChE),253
290,Acetylcholine level,253
287,Acetylcholine,253
289,Acetylcholine (Ach) level,253
4527,syntactic errors,254
3183,SPMSQ >= 4 errors,254
4130,errors in language production,254
3558,Thalamus,255
3557,Thalamic dysfunction,255
3566,Thigmotactic behavior,255
3567,Thigmotaxis,255
2682,P2X7 receptor,256
2974,Purinergic P2X7 receptor,256
2680,P2X4,256
2683,P2X7R,256
2681,P2X7,256
3706,Vascular biomarkers,257
3963,blood biomarkers,257
3965,blood-based biomarkers,257
4593,various other experimental biomarkers,257
2952,Prognostic biomarkers,257
3988,cardiovascular biomarkers,257
2879,Plasma AD biomarkers,257
2903,Plasma biomarkers,257
1358,Digital biomarkers,257
2123,Iron metabolism biomarkers,257
755,Biomarkers,257
764,Blood biomarkers,257
2613,Nongenetic biomarkers,257
4261,markers of angiogenesis,257
772,Blood-based biomarkers,257
4099,digital biomarkers,257
2186,LRP1,258
2515,NLRP3,258
2516,NLRP3 inflammasome,258
2185,LRP-1,258
4249,lvPPA,258
4488,sLRP1,258
1629,Free-fatty acids (FFA),259
4438,plasma n-3 fatty acids,259
3217,"Saturated fatty acids (14:0, 16:0)",259
4320,n-3 Polyunsaturated Fatty Acids (n-3 PUFA),259
1579,Fatty Acids,259
4321,n-3 fatty acids,259
2907,Plasma fatty acids,259
3216,Saturated fatty acids (14:0 and 16:0),259
2857,Physical activity (PA),260
2858,Physical activity levels,260
3219,Sedentary lifestyle,260
2854,Physical Activity Scale for the Elderly (PASE),260
2226,Lifestyle activities,260
1497,Exercise,260
2856,Physical activity,260
320,Aerobic exercise,260
3141,SEMA4D,261
3140,SE,261
3222,Semagacestat,261
3220,Sele,261
2762,PP2A,262
2763,PPAR,262
278,PPQSA,262
2764,PPAR delta,262
2765,PPAR gamma,262
2767,PPAR-γ,262
2769,PPARGC1A,262
2770,PPARγ,262
1868,Health Utility Index (HUI),263
1428,EPA,263
2724,PE,263
2814,Pe (Error Positivity),263
2382,Medium Chain Triglycerides (MCTs),264
3638,Triglycerides (TG),264
3242,Serum triglyceride (TG),264
4583,triglycerides,264
3637,Triglycerides,264
3639,Triglycerides levels,264
3636,Triglyceride,264
3243,Serum triglycerides,264
996,"CYP2D6, CYP3A4, CYP3A5",265
997,CYP3A4,265
998,CYP3A5,265
1000,CYP46A1,265
999,CYP450,265
995,CYP2D6,265
1001,CYP46A1 rs754203,265
3080,Retinal Vessel Density,266
3078,Retinal Nerve Fiber Layer (RNFL) Thinning,266
3079,Retinal Nerve Fiber Layer (RNFL) thickness,266
3083,Retinal thickness,266
3082,Retinal nerve fiber layer thickness,266
2651,Ornithine transcarbamylase (OTC),267
4407,pan-tyrosine phosphorylated Abl,267
3654,Tyrosine Hydroxylase Enzyme,267
2833,Phospho-Abl (pan-tyrosine),267
3274,Solanezumab,268
3948,bapineuzumab,268
4504,solanezumab,268
721,Bapineuzumab,268
831,C4d,269
1375,Dll4,269
1272,DDIT4,269
1108,Ch4p,269
1106,Ch4a-i,269
952,CPNE4,269
921,CHL1,269
1334,Depressive symptoms,270
1745,Generalized Anxiety Disorder (GAD-7),270
730,Beck Depression Inventory (BDI),270
462,Anxious-Depressive-Like Behavior,270
461,Anxiety,270
2356,Major depression,270
3333,Subclinical Depression,270
2421,Mid temporal (% TIV),28
4299,mid temporal volume,28
4433,planum temporale in STG,28
4568,temporal pole,28
4101,donepezil,272
2131,J147,272
2132,J147 + Donepezil,272
1376,Donepezil,272
2796,Palmitic acid,273
230,APP palmitoylation,273
2797,Palmitoleic acid,273
1564,FYN palmitoylation,273
3737,Visuospatial,274
3738,Visuospatial Function,274
3739,Visuospatial Processing,274
3740,Visuospatial/Constructional score,274
3741,Visuospatial/constructional domain score,274
3736,Visuoconstructional/Executive function,274
4618,β-OHB,275
4619,β-Sitosterol (BS),275
4620,β-actin,275
4628,β-catenin,275
4617,β-NGF,275
4632,β-wrapin AS69,275
4633,β1−γ,275
4634,β2−γ,275
1390,Dynamic cross-frequency coupling (CFC) patterns,276
1630,Frequency magnitudes,276
370,Amplitude Low Frequency Fluctuation (ALFF),276
3629,Treg Frequencies,276
2505,NF-L,277
2603,Nfh,277
2597,NfH,277
2754,PIGF,277
2744,PHF,277
2794,PWF,277
2349,Macrophage-derived chemokine,278
3570,"Thymus and activation-regulated chemokine [TARC, CCL17]",278
2350,"Macrophage-derived chemokine [MDC, CCL22]",278
2461,"Monocyte chemoattractant protein-1 [MCP-1, CCL2]",278
2462,"Monocyte chemoattractant protein-4 [MCP-4, CCL13]",278
431,Amyloid-PET,8
387,Amyloid PET imaging,8
421,Amyloid scan,8
3896,amyloid PET,8
3898,amyloid PET imaging,8
3899,amyloid Positron Emission Tomography,8
390,Amyloid PET scan,8
447,Amyloid-β PET,8
419,Amyloid positivity,8
384,Amyloid PET,8
388,Amyloid PET imaging with 18F–FDDNP,8
392,Amyloid PET-CT,8
389,Amyloid PET positivity,8
391,Amyloid PET testing,8
441,Amyloid-related imaging abnormalities with edema or effusions (ARIA-E),8
1617,Foveal Avascular Zones (FAZ),280
4414,perilesional areas,280
3981,c-Fos-stained neurons,280
3952,basal nucleus of Meynert,280
2975,Purkinje cell layer cellularity,280
2335,MRglc in posterior cingulate region,280
2580,Neurofilament proteins,281
2583,Neuron Specific Enolase (NSE),281
2584,Neuropeptide Y (NPY),281
46,200 kDa neurofilament,281
2593,Neurotrophin concentration,281
3890,agitation,282
1178,Cohen-Mansfield Agitation Inventory,282
326,Agitation,282
3256,Sleep Patterns,283
734,"Behaviors (e.g., getting out of bed at odd hours, going to bed earlier)",283
3254,Sleep Disorder Inventory (SDI),283
2608,Night behavioral disturbances,283
3019,REM sleep changes,283
3018,REM sleep behavior disorder,283
2786,PSG confirmation of REM sleep without atonia,283
3259,Sleep activity,283
4500,sleep disturbances,283
4474,right inferior temporal gyrus fALFF,284
4240,left superior temporal gyrus (STG),284
4237,left inferior temporal gyrus (ITG),284
4234,left inferior frontal gyrus (IFG),284
4235,left inferior parietal gyrus,284
3099,Right Inferior Temporal Gyrus (R ITG),284
752,Bilateral anterior fusiform gyrus (FG) atrophy,284
3101,Right Superior Temporal Gyrus (R STG),284
753,Bilateral anterior inferior temporal gyrus (ITG) atrophy,284
4236,left inferior temporal gyrus,284
2424,Middle Frontal Gyrus (MFG),284
2202,Left Inferior Frontal Gyrus (L IFG),284
3345,Superior temporal gyrus,284
2203,Left Inferior Temporal Gyrus (L ITG),284
2214,Left supramarginal gyrus (SMG) atrophy,284
2212,Left posterior temporal gyrus atrophy,284
2211,Left inferior frontal gyrus (IFG) atrophy,284
3346,Superior temporal gyrus (STG) atrophy,284
4300,middle and inferior frontal gyri,284
2768,PPAR-δ agonist,285
2760,PLVβ2 → γ,285
2766,PPAR-β/δ,285
2761,PLVθ → β1,285
4638,δ−α2,285
2368,Mean atrophy,286
511,Atrophy (global and local),286
1105,Ch4 subfield atrophy,286
4447,precuneus atrophy,286
2934,Precuneus atrophy rate,286
514,Atrophy progression,286
2668,P-tau217 levels,287
2664,P-tau,287
4462,p‐tau (AT8),40
253,AT8 (Ser(P)202/Thr(P)205)-positive Tau,40
254,AT8-positive Tau,40
2740,PG5 (Ser(P)409)-positive Tau,40
2663,P-Tau,40
4189,higher t-tau and p-tau levels,40
1259,DA9-positive Tau,40
4362,p-tau levels,40
2976,P‐tau,40
4351,p-Tau,40
4355,p-Tau levels,40
4358,p-tau,40
4326,network failure quotient (NFQ),288
2506,NF-κB,288
2511,NFκB,288
2566,Neural Flexibility Quotient (NFQ),288
3367,Systemic immune-inflammation index,289
4219,inflammatory markers,289
4065,chronic inflammatory mechanisms,289
2085,"Inflammatory markers (e.g., Map3k7, Map2k4, C1qa, C1qb, C3, C4a, Flt1)",289
2084,Inflammatory markers,289
2083,Inflammatory factors,289
2080,Inflammation biomarkers,289
2079,Inflammation,289
4217,inflammatory biomarkers,289
1513,FBB PET,290
3415,TIB,290
2636,OLB,290
1512,FBB,290
1547,FJB,290
1398,EB,290
3021,RHOB,290
2997,R-WAB AQ,290
2932,Praxis test,291
60,30-second chair stand test (CST),291
2855,Physical Performance Test (PPT),291
722,Barcelona Test-Revised (TBR),291
2125,Isaac’s set test,291
1591,Flanker test,291
3911,amyloid-beta,8
4622,β-amyloid (1-42),8
438,Amyloid-beta load,8
4621,β-amyloid,8
3910,amyloid β,8
3916,amyloid-β levels,8
3918,amyloid-β1–42,8
2902,Plasma amyloid β,8
3960,beta-amyloid levels,8
439,Amyloid-beta load (CL values),8
4626,β-amyloid protein,8
452,Amyloid-β42,8
3913,amyloid-β,8
437,Amyloid-beta (Aβ42),8
434,Amyloid-beta (Aβ) levels,8
442,Amyloid-β,8
432,Amyloid-beta,8
430,Amyloid β42,8
2880,Plasma Amyloid-β (Aβ),8
446,Amyloid-β 42,8
4616,β amyloid,8
3915,amyloid-β 42/40 ratio,8
450,Amyloid-β protein,8
4627,β-amyloid proteins,8
451,Amyloid-β1–42,8
3956,beta amyloid,8
424,Amyloid β,8
3959,beta-amyloid,8
1405,EDNRA,293
3656,UBE2V1,293
314,Adamts1,293
1406,EDVGSNK,293
3661,UGT8,293
123,ADAM10,293
1404,EDN1,293
3180,SPECT imaging,294
3179,SPECT,294
3181,SPECT scan,294
3182,SPECT-DaTscan®,294
1308,DaTscan®,294
2443,Mitochondrial Function,295
2446,Mitochondrial enzymes,295
4309,mitochondrial quality control,295
4303,mitochondrial bioenergetics,295
2447,Mitochondrial function,295
2448,Mitochondrial quality control markers,295
4305,mitochondrial complex I–III activity,295
4304,mitochondrial biogenesis,295
4308,mitochondrial function,295
2444,Mitochondrial biogenesis-related protein,295
2445,Mitochondrial dysfunction,295
4306,mitochondrial dysfunction,295
4307,mitochondrial dysfunctions,295
2735,PET imaging,296
2316,MRI and PET scans,296
3054,Reduced occipital activity on FDG-PET imaging,296
2928,Posterior cingulate island sign on FDG-PET imaging,296
2926,Posterior cingulate FDG-PET,296
2326,MRI or 18F-FDG PET,296
2315,MRI and FDG-PET measures,296
1560,FTM-PET visual read,296
1522,FDG PET scan,296
1532,FDG-PET imaging,296
3369,Systolic blood pressure,297
769,Blood pressure,297
1953,Hypertension,297
763,Blood Pressure (BP),297
1343,Diastolic BP,297
3368,Systolic BP,297
1056,Cerebral SVD,298
3201,SV2A,298
3202,SVD features,298
3203,SVD score,298
3204,SVD-associated features,298
3205,SVLT,298
1485,Estradiol levels,299
1487,Estrogen levels,299
4131,estradiol to follicle-stimulating hormone ratio,299
1484,Estradiol,299
1486,Estradiol to FSH ratio,299
543,Aβ amyloid angiopathy,8
3235,Serum amyloid A [SAA],8
1058,Cerebral amyloid angiopathy (CAA),8
3077,Retinal Aβ,8
3081,Retinal amyloid index,8
3234,Serum amyloid A (SAA),8
265,AV45-SUVR,301
264,AV45-PET SUVR,301
263,AV45-PET,301
1595,Florbetapir (AV45),301
261,AV-45,301
262,AV-45 Uptake,301
1594,Florbetapir (AV-45),301
1131,Cldn5,302
1134,Clec7a,302
1135,Clic5a,302
928,CLOX1 clock-drawing task,302
930,CLU,302
927,CLOX1,302
926,CLEC7A,302
4469,rCBF in IPL,303
3015,RCFT,303
3020,RFFT,303
4468,rCBF,303
277,Ab274,304
101,AB 42/40 ratio,304
276,Ab,304
100,AB,304
279,Ab42/40 ratio,304
278,Ab42,304
4511,step count,305
3308,Step length (SL) before turning,305
3305,Step Length (SL),305
3304,Step Length,305
3270,Smart-vest steps,305
3307,Step frequency,305
4512,step length,305
3309,Step length variability,305
3310,Step width,305
3306,Step Width,305
569,Aβ protofibrils,8
3277,Soluble Aβ40,8
3276,Soluble Aβ protofibrils,8
3275,Soluble Aβ,8
621,Aβ42 oligomers,8
564,Aβ polymers,8
3278,Soluble Aβ42,8
557,Aβ oligomers (AβOs),8
556,Aβ oligomers,8
445,Amyloid-β (Aβ) protofibrils,8
2845,Phosphorylated tau (P-tau181),40
2846,Phosphorylated tau (p-tau(181)),40
2847,Phosphorylated tau (p-tau),40
2848,Phosphorylated tau (p-tau181),40
2849,Phosphorylated tau (p-tau181p),40
4554,tau protein phosphorylation,40
2850,Phosphorylated-Tau (P-Tau),40
2851,Phosphorylated-Tau (p-Tau) in blood,40
2852,Phosphorylated-tau,40
3506,Tau (total tau and phosphorylated tau),40
4560,tau-phosphorylated,40
1945,Hyperphosphorylated tau,40
1946,Hyperphosphorylated tau (PHF1),40
1947,Hyperphosphorylated tau (p-tau),40
1948,Hyperphosphorylated tau (phospho-tau),40
1949,Hyperphosphorylated tau protein,40
4207,hyperphosphorylated tau,40
3517,Tau hyperphosphorylation,40
4359,p-tau (phosphorylated tau proteins),40
4547,tau hyperphosphorylation,40
2844,Phosphorylated tau (P-tau),40
4208,hyperphosphorylated tau protein,40
2842,Phosphorylated Tau (p-tau181),40
4431,phosphorylated-tau,40
2915,Plasma phosphorylated tau (p-tau),40
3523,Tau phosphorylated at threonine 181 (p-tau181),40
3524,Tau phosphorylation,40
4430,phosphorylated tau (ptau),40
4429,phosphorylated tau (p-tau181),40
4551,tau phosphorylated at threonine 181 (p-tau),40
3522,Tau phosphorylated at threonine 181,40
2843,Phosphorylated tau,40
3521,Tau phosphorylated at Ser235 (MC6),40
3520,Tau phosphorylated at Ser202/Thr205 (AT8),40
4427,phosphorylated tau,40
4552,tau phosphorylation,40
1943,Hyperphosphated tau protein,40
1944,Hyperphosphorylated Tau,40
2841,Phosphorylated Tau,40
4428,phosphorylated tau (p-tau),40
527,Axon Peptide 108,308
2048,IgG against Axon Peptide 108,308
820,C-peptide (ICP),308
738,Berberine,309
3869,[18F]dihydromethidine,309
4592,valproate,309
1866,Hcy,309
1926,Histamine,309
2107,Intepirdine,309
2219,Levetiracetam,309
3703,Valine,309
2126,Isoleucine,309
1733,Gamma sensory stimulation therapy effect on sleep,310
2476,Music therapy (MT),310
4536,tDCS stimulation,310
1198,Constant Therapy performance,310
2420,Microvasculature genes,311
4002,cerebral perfusion,311
108,Cerebral microbleeds,311
1072,Cerebral microbleeds (CMBs),311
78,Blood-Brain Barrier (BBB) Permeability,311
1902,Hippocampal perfusion,311
1399,EB extravasation,311
709,BMS,312
701,BHB levels,312
695,BDS,312
687,BDI-II,312
759,Blautia,312
93,A2m,312
700,BHB,312
3063,Regulatory T cells (Tregs),313
878,CD4+CD25+Foxp3+ regulatory T cells (Tregs),313
3635,Triggering receptor expressed on myeloid cells 2 (TREM2),313
3451,TREM2 mutation,313
3630,Treg cells,313
1837,HMOX,314
2619,Notch,314
2307,MNA,314
2649,Orexin,314
173,ALT,314
2353,Maff,314
2284,MHIS,314
2628,Nuts,314
970,CSDD total,315
968,CSDD Behavioral disturbance,315
967,CSDD,315
966,CS metric,315
969,CSDD Mood-related signs,315
1011,Cannabinoid-2 receptor,316
1620,Fractalkine receptor,316
1180,Colony-stimulating factor 1 receptor,316
1254,D2-like receptors,316
1253,D1-like receptors,316
1252,D1 receptor,316
3385,TAM receptor,316
2642,Oleanolic Acid (OA),317
1452,"Eicosanoid metabolites (e.g., DHA, 9-HETE, 8-iso-15-keto PGF2β, 11- and 13-HDoHEs, 9- and 13-HODEs)",317
1453,Eicosanoids,317
1451,Eicosanoid metabolites,317
4117,eicosapentaenoic acid (EPA),317
2906,Plasma eicosapentaenoic acid (EPA),317
2801,Parathyroid hormone (PTH),318
3457,TSPO (18 kDa translocator protein),318
358,Thyroid-Stimulating Hormone (TSH),318
3459,TSPO expression in thalamus,318
3458,TSPO expression in hypothalamus,318
3029,RMTG hypometabolism,319
2397,Meningioma,319
3541,Temporoparietal hypometabolism,319
1954,Hypoalbuminemia,319
3168,SNX17,320
3115,S100b,320
3114,S100B,320
3117,S24-7,320
3113,S100A12,320
3116,S100β,320
4635,γ-glutamyl amino acids,321
1779,Glutamine,321
1780,Glutamine synthetase,321
1778,Glutamate,321
4177,glutamate,321
1781,Glutamine synthetase (GS),321
1735,Gamma-Glutamyl Transferase (GGT),321
2242,Lower BBS scores,322
678,BBB disruption,322
679,BBS,322
519,Automated parcellation,323
3286,Spatial navigation,323
208,"In-home activity data (computer use, walking speed, time out of house)",323
2819,Performance-Oriented Assessment of Mobility (POMA),323
2357,Malformation of venous development,324
3705,Vascular abnormalities,324
3249,Single cavernous malformation,324
2977,Q,325
2982,QEEG,325
1506,FAB,325
1508,FAK,325
2279,MFG1,326
2408,Mfn2,326
2407,Mfn1,326
2278,MFG,326
2272,MEF2C,326
2282,MFN2,326
2281,MFN1,326
760,Blessed ADL,327
762,Blessed score ADL,327
761,Blessed Test,327
1422,EFEs (Emotional Facial Expressions),328
1567,Facial gender recognition test,328
1507,FACIAL EMOTION RECOGNITION,328
1566,Facial emotion recognition test,328
4118,emotional arousal,328
1647,Functional MRI (fMRI),329
308,Resting State Functional MRI (rsfMRI),329
4158,functional magnetic resonance imaging (fMRI),329
788,"Brain MRI findings (widening of sulci in fronto-insular, occipital, and olfactory sulci)",329
4133,fMRI,329
3146,SG performance data,330
2951,Processing speed,330
1511,FAST,330
3208,SWM performance,330
2641,Odoribacter,331
3651,Turicibacter,331
751,Bifidobacterium,331
3311,Streptococcus,331
89,Bacteroidetes,331
88,Bacteroides (enterotype I),331
87,Bacteroides,331
302,Actinobacteria,331
1489,Eubacterium rectale,331
1568,Faecalibacterium,331
1483,Escherichia/Shigella,331
1175,"Cognitive tasks (visual oddball, flanker, n-back, delayed match-to-sample)",332
2826,Perspective-taking tests,332
4472,"references to objects, subjects and actions",332
733,Behavioral observations,332
3272,"Social cognition tests (e.g., facial recognition, perspective taking)",332
3502,Task Activation Responses,332
4418,phospho-GSK-3 beta S9 (S9-GSK-3β),333
1705,GSK-3β,333
1704,GSK-3B,333
1708,GSK3B,333
1709,GSK3β,333
1707,GSK3,333
3646,Trypan blue dye exclusion assay,334
737,Benton Visual Retention Test (BVRT),334
1556,FRAP assay,334
4556,tau tangles,40
4561,tau-positive neuropil threads,40
3514,Tau filaments,40
3526,Tau protein tangles,40
2573,Neurofibrillary tangles (tau protein),40
3507,Tau Neurofibrillary tangles,40
3680,VDRL,336
3690,VL,336
4590,vMRI,336
3700,VWF,336
3699,VSRAD,336
3692,VLDL,336
2225,Life-space characteristics,337
1606,FluoSphere beads,337
1263,DAMPs,337
81,BORB,338
807,BrdU,338
852,CB2R,338
853,CBF,338
3070,Resting CBF,338
91,A1 astrocyte phenotype,339
92,A2 astrocyte phenotype,339
4343,oligodendrocytes,339
3943,astrocytes,339
507,Astrocytes,339
3194,SUVR in caudate,340
3195,SUVR in globus pallidus,340
3196,SUVR in putamen,340
3197,SUVR in thalamus,340
1246,Cytochrome c,341
1247,Cytochrome c oxidase (COX),341
1243,Cyclooxygenase,341
860,CCO (Cytochrome C Oxidase),341
1037,Centiloid scale assessments,342
1039,Centiloid value,342
1040,Centiloids,342
1038,Centiloid threshold values,342
1036,Centiloid method,342
1035,Centiloid (CL),342
3982,c-fos,343
1616,Fos,343
1561,FTO,343
1557,FSH,343
1558,FSH levels,343
3543,Tenericutes,344
4089,curcumin,344
1239,Curcumin,344
3542,Tenascin-R,344
1251,D-serine,345
1250,D-KEFS,345
817,C-DF,345
1264,DAN alterations,345
3608,Touch,346
1194,Computer-based touchscreen cognitive task,346
3252,Six-Item Screen (SIS),346
2292,MMN,347
2296,MMQ,347
2144,K-MMSE,347
2300,MMSE score,347
2297,MMSE,347
2291,MME,347
2306,MMSE-2:SV,347
2303,MMSE-2,347
2305,MMSE-2:EV,347
2302,MMSE scores,347
2301,MMSE score < 17,347
2304,MMSE-2:BV,347
69,4G8,348
2258,MB,348
64,3MS,348
77,6MWT,348
8,4SBT,348
983,CSF1R,349
158,AFF1,349
1967,ICVF,349
1418,EF,349
905,CELF1,349
1809,Grey matter volumes,350
3584,Total Gray Matter Volume,350
1802,Grey Matter Density,350
1799,Gray Matter Volume,350
11,129Xe signal in gray matter,350
1801,Gray matter volume,350
1798,Gray Matter (GM) volume,350
1800,Gray Matter Volume (GMV),350
1808,Grey matter volume,350
1805,Grey Matter Volume,350
1099,Cerebrospinal fluid T-tau/Aβ42,351
1100,Cerebrospinal fluid p-Tau,351
1096,Cerebrospinal fluid Aβ42/40,351
1097,Cerebrospinal fluid Aβ42/40 ratio,351
1101,Cerebrospinal fluid t-tau,351
1098,Cerebrospinal fluid P-tau/Aβ42,351
917,CGA-NPI,352
2533,NPI total score,352
2532,NPI scores,352
2538,NPI-NH total,352
2539,NPI-Q,352
2542,NPID+A,352
2534,NPI-NH,352
2531,NPI,352
1814,Gut Microbiota,353
4184,gut microbiota,353
1818,Gut microbiota,353
1819,Gut microbiota composition,353
1817,Gut microbiome diversity,353
1816,Gut microbiome,353
3297,Spindle power,354
3170,SO/spindle coupling strength,354
3296,Spindle Power,354
2607,Nicotinic α7 receptors,355
2606,Nicotinic binding,355
4614,α7 nicotinic acetylcholine receptor (α7nAChR),355
4615,α7 nicotinic acetylcholine receptors (α7 nAChRs),355
526,Axl,356
528,Axona,356
273,AXL,356
1774,Glucose metabolism (FDG-PET),357
1530,FDG-PET glucose metabolism measures,357
1536,FDG-PET-derived metabolic measures,357
20,18F-FDG (glucose metabolism),357
1529,FDG-PET cerebral metabolic rate of glucose,357
162,AKT,358
328,Akt,358
163,AKT1,358
164,AKT3,358
829,C3ar1,359
828,C3ar,359
826,C3,359
827,C3 signaling,359
830,C3b,359
3951,basal forebrain volume,360
725,Basal forebrain atrophy,360
3950,basal forebrain atrophy,360
726,Basal forebrain volume,360
3949,basal forebrain,360
58,3-Hydroxybutyrate,361
3244,Serum β-hydroxybutyrate (BHB),361
59,3-hydroxybutyrate,361
4629,β-hydroxybutyrate,361
4145,florbetapir SUVr,362
4142,florbetapir,362
1597,Florbetapir F-18 PET,362
1593,Florbetapir,362
4144,florbetapir PET,362
35,18F-florbetaben PET,362
1598,Florbetapir PET,362
1596,Florbetapir F 18 PET,362
1600,Florbetapir-PET,362
1599,Florbetapir PET SUVR,362
332,Albumin (ALB),363
3233,Serum albumin,363
3891,albumin + IVIG,363
333,Albuminemia,363
331,Albumin,363
947,COR,364
1692,GP-Cog,364
2432,Mini-Cog,364
3410,TH17 cells,365
3553,Th17,365
3551,Th1 cells,365
3555,Th2 cells,365
3554,Th17 cells,365
1580,Ferritin,366
4137,ferritin,366
2122,Iron,366
1540,FES,366
1539,FERMT2,366
1541,FETZ-test,366
3149,SIB,367
3150,SIB-L,367
3148,SI,367
3151,SIB[lang],367
1624,Fractional anisotropy (FA),368
1621,Fractional Anisotropy,368
1623,Fractional anisotropy,368
1622,Fractional Anisotropy (FA),368
1626,Fractional anisotropy (FA) of left uncinate fasciculus (UF),368
3846,[11C]acetate,369
3844,[11C]PK-11195,369
3842,[11C]PBR28,369
3841,[11C]Ascorbic,369
3847,[11C]dehydroascorbic acid,369
3840,[11C]-l-deprenyl-D2,369
0,11C-(R)-PK11195,369
1,11C-DAA1106,369
2,11C-DED,369
3,11C-PBR28,369
287,PDE4B,370
288,PDE9,370
2723,PDM,370
286,PD-1,370
1886,High-sensitivity C-reactive protein (hs-CRP),38
4187,high-sensitivity C-reactive protein,38
3239,Serum high-sensitivity C-reactive protein (hs-CRP),38
3238,Serum high sensitivity C-reactive protein (hs-CRP),38
823,C-reactive protein [CRP],38
822,C-reactive protein (CRP) levels,38
821,C-reactive protein (CRP),38
816,C reactive protein,38
1885,High-sensitivity C-Reactive Protein (hsCRP),38
324,Age at diagnosis,372
323,Age,372
159,AGEs,372
2149,Ketogenic diet,373
2151,Ketones (BHB),373
4608,α-ketoglutarate,373
2150,Ketones,373
3590,Total antioxidant capacity (TAC),374
3579,Total Antioxidant Capacity (TAC),374
2918,Plasma total antioxidant capacity (TAC),374
3191,SUVR,375
1514,FBB SUVR,375
1515,FBP SUVR,375
2862,PiB SUVR,375
1190,Composite PET SUVR,375
1191,Composite SUVR,375
3192,SUVR 18F-FBP,375
685,BCG therapy,376
684,BCG,376
683,BCAAs,376
682,BCAA,376
729,Bcl-2,376
686,BCL2,376
3585,Total Phonation Time,377
3627,Transformed Phonation Rate,377
2831,Phonation Rate,377
232,APP/PS1 mutation carriers,378
2785,PSEN2 mutations,378
2783,PSEN1 mutations,378
2782,PSEN1 mRNA,378
2777,PS1 mutation,378
2776,PS1 gene mutation,378
876,CD4+ T cells,379
877,CD4+/CD8+ ratio,379
879,CD4+CD25− T cells (Teffs),379
880,CD45high cells,379
886,CD8 cells,379
887,CD8+ T cells,379
888,CD8+ TEMRA,379
3407,TGF-β2,380
3408,TGFα,380
3409,TGFβ,380
3406,TGF-β1,380
3404,TGF-α,380
3405,TGF-β,380
3907,amyloid plaque deposition,8
3917,amyloid-β plaques,8
426,Amyloid β (Aβ) plaques,8
3908,amyloid plaques,8
436,Amyloid-beta (Aβ) plaques,8
440,Amyloid-beta plaques,8
444,Amyloid-β (Aβ) plaques,8
4625,β-amyloid plaques,8
418,Amyloid plaques (Aβ1–42),8
449,Amyloid-β plaques,8
416,Amyloid plaque deposition,8
3968,brain amyloid plaque,8
403,Amyloid beta peptides (Aβ) plaques,8
393,Amyloid Plaques (Aβ),8
417,Amyloid plaques,8
2478,Myo-inositol,382
4315,myo-inositol (mI),382
4316,myo-inositol (mI)/creatine (Cr),382
1293,DR,383
1296,DRS-2,383
1382,Dr,383
1295,DRS,383
2229,Lipid peroxidation,384
2232,Lipopolysaccharides (LPS),384
2231,Lipid profiles,384
2230,Lipid peroxides,384
2269,MDA lipid peroxidation marker,384
4069,classical monocytes,385
2463,Monocytes,385
4312,monocytes,385
4340,non-classical monocytes,385
4226,intermediate monocytes,385
913,CFC,386
914,CFT,386
915,CFr,386
756,Blalock Alzheimer's Disease Up pathway,387
757,Blalock Alzheimer’s Disease Down pathway,387
758,Blalock Alzheimer’s Disease Up pathway,387
1974,IFNɣ,388
198,IFG,388
1970,IFB-2,388
2156,L IFG orbitalis,388
2200,Left IFG orbitalis,388
503,Asiaticoside,389
502,Asiatic acid (AA),389
501,Asiatic acid,389
3942,asiatic acid,389
1339,Diabetes Management,390
1338,Diabetes,390
1340,Diabetes Mellitus,390
1341,Diabetes mellitus,390
4197,hippocampal-sparing atrophy,391
1897,Hippocampal atrophy,391
4409,parahippocampal atrophy,391
1898,Hippocampal atrophy in CA1 subfield region,391
1900,Hippocampal atrophy rates,391
4199,hippocampus atrophy,391
1888,Hippocampal Atrophy Rate,391
4192,hippocampal atrophy rate,391
1887,Hippocampal Atrophy,391
1901,Hippocampal formation atrophy,391
1904,Hippocampal subfield atrophy,391
1912,Hippocampal/parahippocampal atrophy,391
1915,Hippocampus and precuneus atrophy,391
1916,Hippocampus atrophy rate,391
4191,hippocampal atrophy,391
1183,Complement C3,392
1185,Complement system components,392
1747,"Genes (complement receptor 1, CD33, TREM2)",392
1184,Complement proteins,392
4149,flutemetamol (18F),393
4148,flutemetamol,393
3860,[18F]Flutemetamol,393
1610,Flutemetamol F 18,393
1611,Flutemetamol F 18 Injection,393
40,18F-flutemetamol PET,393
3853,[18F]-flutemetamol,393
1609,Flutemetamol,393
3875,[18F]flutemetamol PET,393
3874,[18F]flutemetamol,393
109,ACE category fluency,394
1017,Category Fluency,394
1018,Category fluency,394
1019,Category fluency test,394
1020,Category fluency test scores,394
4613,α-synuclein pathology biomarkers,395
342,Alpha-synuclein,395
4575,total alpha-synuclein,395
4612,α-synuclein,395
4059,cerebral spinal fluid α-synuclein,395
4535,t-α-synuclein,395
199,APOE ε4 allele,396
213,APOE4 allele,396
196,APOE ε2 allele,396
190,APOE e4 allele,396
217,APOEε4 allele,396
202,APOE ε4-allele,396
480,ApoE4 allele,396
475,ApoE ε4 allele,396
4253,mALFF/mfALFF values in the precuneus,397
4252,mALFF values in the precuneus,397
4250,mALFF values,397
244,ARIA-H,398
242,ARIA,398
243,ARIA-E,398
890,CDK5 kinase,399
2133,JAK inhibitors,399
2134,JAK kinases,399
175,AMP-activated protein kinase,399
1661,Fyn kinase,399
1612,Fms-like tyrosine kinase 1 [FLT-1],399
4389,p70S6 kinase,399
4390,p70S6 kinase (p70S6K),399
3655,Tyrosine kinase-2 [Tie-2],399
1245,Cystatin C,400
3744,Vitamin C,400
1244,Cys C,400
1242,Cyanocobalamin,400
1241,CyPA,400
2500,NBM,401
2557,NbM volume,401
2556,NbM measurement,401
3676,VBM,401
235,APPsw,402
223,APP fragments,402
234,APPSwe,402
233,APP23,402
226,APP levels,402
231,APP-FL,402
220,APP,402
229,APP p.A673T,402
3931,apoE genotype,403
3937,apoe4 genotype,403
477,ApoE-E4 gene,403
470,ApoE genotype,403
205,APOE-ɛ4 genotype,403
214,APOE4 genotype,403
201,APOE ε4 genotype,403
197,APOE ε3 genotype,403
192,APOE genotype,403
472,ApoE proteotype,403
478,ApoE-E4 genotype,403
48,ApoE genotyping,403
481,ApoE4 genotype,403
2419,Microinfarcts,404
1068,Cerebral infarcts,404
2075,Infarct presence,404
1766,Global Microbleed and Infarct Presence,404
1014,Carotid Intima-Media Thickness (CCA-IMT),405
3342,Substantia innominata (SI) thickness,405
1435,ERC thickness,405
2456,Molecular layer thickness,405
3648,Tumor necrosis factor alpha (TNFα),406
3649,Tumor necrosis factor alpha [TNF-α],406
3650,Tumor necrosis factor beta [TNF-β],406
3647,Tumor Necrosis Factor (TNF),406
515,Attention,407
3544,Test of Everyday Attention,407
1187,Complex attention,407
3546,Tests of Attention: Trails A and B,407
3248,Simple Attention,407
344,Altoida DNS,408
1357,Digital Neuro Signature (DNS),408
345,Altoida Digital Neuro Signature (DNS),408
2094,Insular lobe,409
4268,medial temporal lobe volumes,409
4267,medial temporal lobe structures,409
4266,medial temporal lobe network,409
2807,Parietal lobe,409
2378,Medial temporal lobe volumes,409
2377,Medial temporal lobe volume,409
3923,anterior lobe structures,409
3064,Relative preservation of medial temporal lobe structures on CT/MRI,409
383,Ventricles (% TIV),410
4595,ventricles volume,410
4596,ventricular volume,410
384,Ventricular volume,410
3011,RBANS subtest scores,411
3012,RBANS total scale index scores,411
3010,RBANS scores,411
3013,RBANS total score,411
3008,RBANS,411
3009,RBANS Total Score,411
3828,Y maze,412
2467,Morris Water Maze Performance,412
2468,Morris water maze,412
1880,High Cholesterol,413
3241,Serum total cholesterol,413
1116,Cholesterol,413
4061,cholesterol,413
2904,Plasma cholesterol,413
3581,Total Cholesterol,413
3595,Total cholesterol (TC),413
1117,Cholesterol levels,413
3594,Total cholesterol,413
2257,MAPT mutations,414
2256,MAPT,414
4384,p38 MAPK,414
2255,MAP-2,414
4330,neurofilament light,415
4331,neurofilament light (NfL),415
4332,neurofilament light chain,415
4333,neurofilament light chain (NFL),415
2576,Neurofilament light chain,415
2599,NfL (Neurofilament light chain),415
2600,NfL (Neurofilament light),415
2579,Neurofilament light chain (NfL) in CSF,415
2578,Neurofilament light chain (NfL),415
2577,Neurofilament light chain (NFL),415
2575,Neurofilament light (NfL),415
2574,Neurofilament light,415
768,Blood neurofilament light (NfL),415
2601,NfL (Neurofilament-light chain),415
4439,plasma neurofilament light chain,415
2081,Inflammatory Bowel Disease,416
781,Bowel Movements,416
1235,Crohn’s Disease,416
368,Ulcerative Colitis,416
2962,Proportion of words spoken by participants,417
3819,Word count in conversations,417
3817,Word Frequency,417
2960,Proportion of spoken words during free conversation,417
2961,Proportion of spoken words in conversation,417
4454,proportion of word counts,417
1465,Enterotype I,418
1466,Enterotype III,418
2652,Other bacteria (enterotype III),418
67,4-item Instrumental Activities of Daily Living scale (IADL-PAQUID) score,419
152,ADL (activities of daily living),419
2091,Instrumental Activities of Daily Living (IADLs),419
308,Activities of Daily Living (ADLs),419
1961,IADL (instrumental activities of daily living),419
307,Activities of Daily Living (ADL) scale score,419
151,ADL (Activities of Daily Living),419
988,CTF-α,420
221,APP CTFs,420
989,CTF-β,420
3261,Slow Oscillations (SO),421
3262,Slow Wave (SW) activity,421
3265,Slow wave,421
3266,Slow wave latency,421
4502,slow waves,421
3267,Slow-wave sleep (SWS),421
4245,lowSWA (low-frequency slow wave activity),421
4215,induced second slow-wave peak,421
925,CIBIS-plus,422
924,CIBIC-plus,422
923,CIBIC-Plus,422
922,CIBIC,422
2413,Microglia,423
2249,M2 microglia,423
304,Activated microglia,423
4298,microglial activation,423
2415,Microglial activation,423
2414,Microglia activation,423
4297,microglia,423
2247,M1 microglia,423
2248,M1-type microglia,423
3353,Symbol Digit Modalities Test (SDMT),424
1356,Digit-symbol substitution,424
1351,Digit Symbol,424
3587,Total Tau,40
4581,total-tau,40
3602,Total tau (T-tau),40
3607,Total-Tau (T-Tau),40
3601,Total tau,40
4582,total-tau (t-tau),40
3606,Total-Tau,40
4579,total tau (t-tau),40
4578,total tau,40
3604,Total tau (t-tau),40
3603,Total tau (t-Tau),40
2405,Methylene Blue,426
2406,Methylene Blue (MB),426
775,"Bluish color temperature (4,440–9,325 K)",426
1491,Evans Blue (EB),426
4120,endosome volume,427
2367,Mean Endosome Volume (MEV),427
4123,enlarged endosomes,427
4119,endosome number,427
1461,Endosomal volume,427
3752,WAIS-IV Coding,428
3247,Similarities (WAIS-III),428
2361,Matrices (WAIS-III),428
2029,IQ-CODE,428
3784,Wechsler Adult Intelligence Scale (WAIS),428
185,APLP1,429
1685,GLP-1 Analog,429
2746,PHLPP-2,429
2745,PHLPP-1,429
483,Apold1,429
186,APLP1β17,429
1684,GLP-1,429
1346,Diffuse loss of brain volume,430
3538,Temporal brain volume loss,430
2805,Parietal brain volume loss,430
790,Brain Volume Loss,430
1045,Cerebellum and brain stem volume loss,430
1636,Frontal brain volume loss,430
800,Brain volume loss,430
1502,F2-isoprostanes,431
2127,Isoprostanes (F2-IsoPs),431
79,"8,12-isoiPF(2alpha)-VI",431
1501,F2-IsoPs,431
1695,GPx1,432
1694,GPx,432
1693,GPX,432
1790,Gpb3,432
1791,Gpnmb,432
1786,Glx,432
3919,animals/10 s,433
3920,animals/10s,433
3921,animals/10 s,433
2266,MD,434
986,CT,434
987,CT scan,434
3167,SNCA,434
1859,Hand Grip Strength,435
1810,Grip Strength,435
1860,Hand Movement,435
4186,hand movement analysis,435
740,Berg Balance Scale (BBS),436
680,BBS (Berg Balance Scale),436
739,Berg Balance Scale,436
1179,Collaborative network spontaneous activity,437
1182,Community consistency in SMC,437
1041,Central Executive Network (CEN),437
681,BC (Betweenness Centrality),437
2235,Local efficiency in SMC and DMN,437
3735,Visual network,437
1280,DHEA-s,438
1279,DHEA-S,438
1278,DHA (22:6n-3),438
1277,DHA,438
2759,PLI (Phase Lag Index),439
2827,Phase Locking Value (PLV),439
2828,Phase locking of oscillations,439
1882,High illuminance (350–750 lux),440
2853,Photopic illuminance,440
238,AQP4 polarization,441
236,AQ4,441
237,AQP4,441
3381,TAC,442
3383,TACE activity,442
3382,TACE,442
3384,TAF15,442
2174,LC3A,443
2169,LC3,443
2173,LC3-II,443
2170,LC3 (Atg8),443
2175,LC3B,443
218,LC3-I,443
2172,LC3-I/II,443
2374,Medial Temporal Lobe Atrophy (MTA),444
2375,Medial temporal atrophy,444
2376,Medial temporal lobe atrophy,444
4265,medial temporal lobe atrophy,444
3537,Temporal Lobe Atrophy,444
3924,anterior temporal lobe atrophy,444
382,Ventral and lateral anterior temporal pole (ATP) atrophy,444
298,Across-domain IIV,445
3814,Within-domain IIV,445
4105,dual-task gait cost,446
1385,Dual-task cost,446
1386,Dual-task gait,446
1387,Dual-task gait velocity,446
1388,Dual-tasking impairment,446
2108,Intercellular adhesion molecule-1 [ICAM-1],447
3707,Vascular cell adhesion molecule-1 [VCAM-1],447
3279,Soluble Intercellular Adhesion Molecule-1 (sICAM-1),447
4487,sICAM-1 (Soluble intercellular adhesion molecule 1),447
4494,sVCAM-1 (Soluble vascular cell adhesion molecule 1),447
3922,anterior cingulate cortex,448
4448,precuneus/posterior cingulate cortex,448
457,Anterior Cingulate Cortex (ACC),448
458,Anterior cingulate cortex,448
4445,posterior cingulate cortex,448
2519,NMDA receptors,449
2517,NMDA receptor,449
4498,selective reduction of N-methyl-d-aspartate (NMDA) receptor NR2A density,449
2483,N-methyl-D-aspartate (NMDA) receptor,449
2518,NMDA receptor NR2A density,449
510,Atabecestat,450
3729,Verubecestat (MK-8931),450
521,Avagacestat,450
1827,HDoHes,451
1825,HDL-C,451
1821,HDAC,451
1824,HDL levels,451
1822,HDL,451
1201,Contactin-2,452
1199,Contactin,452
1200,Contactin 2,452
1751,Genetic status,453
1750,Genetic factors,453
1748,Genetic Data,453
1749,Genetic data,453
2623,Number of animals named during TUGdt test,454
3474,"TUGdt ""animals/10 s""",454
2622,Number of animals named during TUGdt,454
3475,"TUGdt ""animals/10 s"" test",454
3484,TUGdt NA animals/10 s,454
3485,TUGdt NA number of animals,454
3488,"TUGdt NA, number of animals",454
3489,TUGdt naming animals (TUGdt NA),454
3487,"TUGdt NA, animals/10 s",454
114,AChE activity,455
113,AChE,455
115,AChE protein levels,455
1756,Giant component size,456
1755,Giant Component Size,456
1921,Hippocampus-PCC circuit,457
1922,Hippocampus-PCC circuit structural connectivity,457
4203,hippocampus-PCC structural connectivity,457
4202,hippocampus-PCC circuit,457
1504,FA of left hippocampus-PCC tract,457
1639,Frontostriatal and hippocampus-PCC circuits,457
1005,Caffeic acid,458
2460,Monocaffeoylquinic acids,458
1008,Caffeoylquinic acids (CQAs),458
1344,Dicaffeoylquinic acids,458
1007,Caffeoylquinic acids (CQA),458
1006,Caffeic acid (CA),458
3831,YKL‐40,459
3830,YKL40,459
3829,YKL-40,459
1494,Executive function,460
1496,Executive functioning,460
1495,Executive function deficits,460
1309,Decline of executive functions,460
1419,EF and L (Executive Function and Learning),460
1493,Executive dysfunction,460
1492,Executive Functioning (EF),460
4605,xenon washout parameter,461
3827,Xenon washout parameter,461
12,129Xe washout half-life,461
3027,RMT,462
3028,RMTG,462
3024,RMBPC,462
4470,rMT,462
3726,Verbal memory,463
3727,Verbal memory function,463
4597,verbal episodic memory performance,463
1479,Episodic memory,463
1481,Episodic memory performance,463
1480,Episodic memory deficits,463
2392,Memory/visuospatial predominant pattern,463
4262,markers of neurogenesis,464
4338,neurotrophic blood-based biomarkers,464
4337,neurotrophic biomarkers,464
2587,Neuroprotective biomarkers,464
3993,ccl2,465
855,CCA-IMT,465
1028,Ccl12,465
228,MDC (CCL22),465
859,CCL11,465
856,CCA-IMT progression,465
858,CCI,465
2697,P3b,466
4385,p3E,466
2689,P3 component,466
2687,P3,466
2488,N1 component,466
2674,P1 component,466
2695,P3a,466
2298,MMSE (Mini Mental State Examination),467
2299,MMSE (Mini-Mental State Examination),467
2441,Mini–Mental State Examination (MMSE),467
2439,Mini-mental State Examination (MMSE),467
2440,Mini-mental state examination (MMSE) score,467
2438,Mini-Mental Status Examination score,467
2437,Mini-Mental State Examination (MMSE) score,467
2436,Mini-Mental State Examination (MMSE),467
2429,Mini Mental State Examination (MMSE),467
2430,Mini Mental State Examination (MMSE) score,467
2431,Mini Mental Status Examination (MMSE),467
2433,Mini-Mental State Exam (MMSE),467
2435,Mini-Mental State Examination (MMS),467
2434,Mini-Mental State Examination,467
2289,MIS-T screening instrument,468
2287,MIS score,468
2288,MIS-T,468
2128,Itga5,469
2039,ITG,469
2201,Left ITG,469
2157,L ITG,469
2129,Itgax,469
2860,Physical performance (SPPB),470
3185,SPPB (Short Physical Performance Battery),470
3184,SPPB,470
1476,Eotaxin-3 [CCL26],48
1475,Eotaxin [CCL11],48
1474,Eotaxin,48
4127,eotaxin,48
4128,eotaxin-3,48
2621,Nucleic acid oxidative modifications,472
1289,DNA methylation,472
1290,DNAm age-acceleration,472
1288,DNA damage,472
4093,cytoplasmic DNA,472
632,Aβ42/t-tau,473
633,Aβ42/t-tau ratio,473
546,Aβ and tau oligomers,473
634,Aβ42/tau ratio,473
631,Aβ42/p-tau,473
583,Aβ/tau level ratios,473
4370,p-tau181/Aβ1-42 ratio,473
4534,t-tau/Aβ1-42 ratio,473
574,"Aβ(1–42), total tau (t-tau), and phosphorylated tau (p-tau)",473
4562,tau/Aβ42 ratio,473
4531,"t-Tau, Phospho-Tau, and Aβ42 combination",473
3530,Tau/Aβ42 ratio,473
597,Aβ1-42/t-tau ratio,473
641,Aβ42IT/t-tauEI,473
3531,Tau:Aβ42 ratio,473
630,Aβ42/P-Tau,473
640,Aβ42IT/p-tauIT,473
2369,Mean diffusivity,474
2366,Mean Diffusivity (MD),474
2370,Mean diffusivity (MD),474
2572,Neurofibrillary tangles (NFTs),475
258,Neurofibrillary tangles,475
2570,Neurofibrillary Tangles (NTFs),475
2450,MoCA score,476
2449,MoCA,476
2308,MOCA,476
2451,MoCA scores,476
3624,Trails A,477
3612,Trail Making B,477
3625,Trails A and B,477
3626,Trails B,477
3610,Trail Making A,477
3611,Trail Making A and B,477
104,ABCA7 rs3764650,478
103,ABCA7 genotype,478
102,ABCA7,478
4501,sleep quality,479
1482,Epworth Sleepiness scale,479
3260,Sleep quality,479
3257,Sleep Quality Index,479
4467,quality of sleep,479
3255,Sleep Efficiency,479
3258,Sleep Quality Scores,479
352,Alzheimer Disease Related Quality of Life (ADRQL),480
2990,Quality of Life in Late-Stage dementia Scale (QUALID),480
2989,Quality of Life - Alzheimer's Disease (QoL-AD),480
1331,Dementia Quality of Life Instrument (DQoL),480
2984,QOL-AD (quality of life-Alzheimer's disease),480
2991,Quality of life (QOL-AD),480
2892,Plasma BACbche gene mRNA levels,481
669,BACbche gene,481
670,BACbche gene gene,481
68,BACbche gene mRNA,481
2891,Plasma BACbche gene mRNA expression,481
381,Vcl,482
3679,VCP,482
3677,VCAM-1,482
3678,VCAM1,482
1417,EEG/MEG,483
2355,Magnetoencephalography (MEG),483
2273,MEG,483
312,Acylcarnitines,484
3887,acyl carnitines,484
2162,L-carnitine (CAR),484
359,Alzheimer’s Disease Assessment Scale-13 (ADAS-Cog 13),485
350,Alzheimer Disease Assessment Scale–Cognitive Subscale (ADAS-Cog),485
365,Alzheimer’s disease Assessment Scale-Cognition (ADAS-Cog),485
361,Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog),485
360,Alzheimer’s Disease Assessment Scale-Cognitive Behavior section (ADAS-Cog),485
355,Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog),485
356,Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog),485
354,Alzheimer's Disease Assessment Scale (ADAS-Cog),485
126,ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale),485
3111,RxR,486
3040,RXR,486
2245,LxR,486
2944,Presenilin genes,487
4449,presenilin-1,487
1395,E280A Presenilin-1 mutation,487
2945,Presenilin-1 mutation,487
4376,p-tau217,40
2426,Mid‐p‐tau231,40
4377,p-tau217Janss,40
1559,FTD-4R tau,40
4380,p-tau231,40
4465,p‐tau217,40
4379,p-tau217WashU,40
2423,Mid-p-tau231,40
4381,p-tau231UGOT,40
2485,N-p-tau217,40
4557,tau-441,40
4378,p-tau217Lilly,40
4374,p-tau181WashU,40
4466,p‐tau231,40
2669,P-tau231,40
4366,p-tau(231),40
3550,TgP301S Tau,40
4365,p-tau(217),40
2678,P231-Tau,40
2694,P301S Tau,40
3528,Tau-P301L,40
2667,P-tau217,40
2630,N‐p‐tau217,40
4352,p-Tau (Ser396),40
4354,p-Tau Ser 396,40
4356,p-Tau ser396,40
4364,p-tau(181),40
1283,DLPFC activity,489
1282,DLPFC,489
1655,Functional connectivity (left DLPFC to right IPL),489
4399,pTau,490
3401,TEMPau,490
2788,PTEN,490
2972,Ptau,490
4457,ptau,490
1378,Dopamine (DA),491
1377,Dopamine,491
4102,dopamine receptors,491
1380,Dopamine depletion,491
1381,Dopamine transporter (DAT),491
1379,Dopamine Transporter,491
2521,NMDAR1,492
4350,p-NMDAR2A,492
2520,NMDAR,492
2522,NMDAR2B,492
3492,TUGst time score,493
3491,TUGdt time,493
3486,TUGdt NA time score,493
3483,TUGdt NA,493
3480,TUGdt MB time score,493
3477,TUGdt MB,493
3473,TUGdt,493
317,Adjusted Flow Index (AFI),494
318,Adjusted flow index (AFI),494
1853,HSP90α,495
1852,HSP90,495
1851,HSP70,495
1850,HSP60,495
1849,HSP40,495
1854,HSP90β,495
4206,hsCRP,495
2840,Phosphor-tau181,40
2836,Phospho-Tau181,40
2835,Phospho-Tau (181P),40
4426,phospho-tau concentrations,40
4425,phospho-tau,40
2834,Phospho-Tau,40
2838,Phospho-tau181,40
2837,Phospho-tau (tau-p181),40
4423,phospho-Tau181,40
2940,Prefrontal activity,497
2939,Prefrontal Activation,497
2941,Prefrontal cortex,497
2942,Prefrontal cortex activity,497
2208,Left caudate-rMFG tract FC,498
3102,Right caudate-rMFG tract AxD,498
2213,Left putamen-rMFG tract fiber number,498
4156,functional connectivity (FC) of the caudate-rMFG tract,498
1516,FC of left caudate-rMFG tract,498
3757,WHO-UCLA AVLT,499
3759,WHO–UCLA AVLT score,499
3760,WHO–UCLA AVLT scores,499
2956,Propionate,500
4453,propionate,500
341,Alpha-syn,501
4610,α-syn,501
4606,α-Syn,501
4405,pThr217,502
4397,pSer202/pThr205,502
4459,ptau181,502
4404,pThr181,502
2789,PTK2B,502
4406,pThr231,502
4403,pTau181,502
4400,pTau Ser396,40
2790,PTP1B,502
1336,Desulfovibrionaceae,503
2946,Prevotella,503
3107,Rikenellaceae,503
3110,Ruminococcaceae,503
2188,Lachnospiraceae,503
2947,Prevotellaceae,503
3682,VEGF-C,504
3681,VEGF,504
3683,VEGF-D,504
3684,VEGFA,504
3685,VEGFR1,504
1960,IADL,505
38,Amsterdam IADL,505
1963,IATI index,505
1962,IAF peak,505
3112,S-IADL,505
2012,IL12P70,506
1986,IL-12P40,506
1988,IL-12p70,506
1987,IL-12P70,506
4382,p11,507
4383,p27,507
2690,P300,507
2677,P200,507
2491,N200,507
4387,p62,507
2700,P50,507
2489,N100,507
4396,pNN50,507
691,BDNF levels,508
693,BDNF-Val66Met polymorphism,508
688,BDNF,508
689,BDNF ApoE,508
692,BDNF plasma levels,508
690,BDNF Met-allele,508
2453,Modified Hachinski Ischemia Scale,509
1857,Hachinski Ischemic Score (HIS),509
2454,Modified Hachinski score,509
2452,Modified Hachinski Ischemia Ratings,509
4600,waist circumference,510
3782,Waist Circumference,510
1062,Cerebral blood flow (CBF),511
3997,cerebral blood flow (CBF),511
1050,Cerebral Blood Flow,511
3059,Regional Cerebral Blood Flow (CBF),511
1053,Cerebral Blood Flow (CBF) in Default Mode Network (DMN),511
1054,Cerebral Blood Flow Velocity (CBFv),511
1061,Cerebral blood flow,511
854,CBF (Cerebral Blood Flow),511
3060,Regional Cerebral Blood Flow (rCBF),511
1051,Cerebral Blood Flow (CBF),511
1052,Cerebral Blood Flow (CBF) in Central Executive Network (CEN),511
2498,NAIP,512
2494,NAA,512
2495,NAA/Cr,512
2496,NAC,512
4565,telomerase,513
3535,Telomere activity,513
4566,telomeres,513
3534,Telomerase activity,513
3072,Resting Treg Compartment,514
3074,Resting Tregs,514
3073,Resting Treg subset,514
3349,Superoxide dismutase (SOD) activity,515
1238,Cu/Zn-superoxide dismutase (SOD),515
3347,Superoxide Dismutase,515
3348,Superoxide dismutase (SOD),515
2916,Plasma superoxide dismutase (SOD) activity,515
3826,Working memory deficits,516
516,Attention deficits,516
2427,Mild cognitive impairment (MCI),516
4073,cognitive deficits,516
1160,Cognitive behavioral deficits,516
1162,Cognitive deficits,516
1167,Cognitive impairment,516
4075,cognitive impairment,516
2655,Oxidative markers,517
2659,Oxidative stress markers (4-hydroxynonenal and 8-hydroxy-2′-deoxyguanosine),517
2658,Oxidative stress biomarkers,517
4346,oxidative stress markers,517
4345,oxidative stress,517
4263,markers of oxidative stress,517
2657,Oxidative stress,517
1361,Dihydrocaffeic acid (DHCA),518
2905,Plasma docosahexaenoic acid (DHA),518
1362,Dihydroferulic acid (DHFA),518
2893,Plasma EPA and DHA levels,518
2530,NPE,519
2544,NPs,519
2543,NPY,519
2615,Norepinephrine,520
4341,norepinephrine,520
2616,Norepinephrine (NE),520
4413,peak VO2,521
3696,VOSP,521
3695,VOR gain,521
3694,VO2max,521
2815,Peak VO2,521
3693,VO2 peak,521
699,BGP,522
1546,FGP,522
3096,RgpB,522
3094,Rey Figure reproduction,523
3093,Rey Complex Figure Test,523
3095,Rey-O,523
2986,QTc interval,524
2985,QTc,524
2978,Q values,524
2416,Microhaemorrhage,525
2417,Microhaemorrhages,525
2418,Microhemorrhages,525
2472,Motor test duration,526
248,Motor test drawing features,526
2470,Motor performance profiles,526
1861,Hand-Motor Performance,526
187,APO E,527
467,Apo A-I,527
3929,apo B,527
468,ApoB,527
456,Anomia,527
1883,High molecular weight adiponectin,528
1838,HMW adiponectin,528
316,Adiponectin levels,528
4062,choline,529
1119,Choline (Cho),529
1118,Choline,529
1666,GABAergic modulation,530
1667,GABAergic synaptic strength,530
1668,GABAergic transmission,530
131,ADAS-Cog scores,531
134,ADAS-Cog13 scores,531
137,ADAS-cog scores,531
129,ADAS-Cog 13-item total score,531
130,ADAS-Cog score,531
974,CSF Aβ42,532
973,CSF Aβ(1–42),532
628,Aβ42/Aβ40 ratio in CSF,532
972,CSF Aβ,532
283,PCC/PCu rCBF,533
169,ALFF combined with ASL in PCC/PCu,533
284,PCC/PCu rCBF and ALFF combination,533
282,PCC/PCu ALFF,533
581,Aβ-specific IgGs,534
579,Aβ-immunoglobulin G (IgG),534
576,Aβ-IgG,534
580,Aβ-specific IgG,534
267,AVLT scores,535
268,AVLT-DR,535
269,AVLT-IR,535
270,AVLT-LDR,535
28,AVLT-SDR,535
272,AVLT-learning,535
266,AVLT,535
4269,melatonin,536
3212,Salivary melatonin,536
2383,Melatonin,536
2703,PACC score,537
2704,PACC-like composite,537
2701,PAC,537
3392,TC,538
3370,T,538
3446,TR,538
3394,TChE,538
3455,TSH,538
3533,Tcf-4,538
3456,TSPO,538
3460,TST,538
1065,Cerebral glucose metabolism,539
3999,cerebral glucose metabolic rate,539
1070,Cerebral metabolic rate of glucose (CMRgl),539
1069,Cerebral metabolic rate for glucose (CMRgl),539
1364,Diminished Cerebral Glucose Metabolism (DCGM),539
3998,cerebral glucose hypometabolism,539
3973,brain glucose metabolism,539
1917,Hippocampus glucose metabolism,539
1064,Cerebral glucose metabolic rate,539
1055,Cerebral Metabolic Rate of Glucose (CMRglc),539
4000,cerebral glucose metabolism,539
3539,Temporal cortex glucose metabolism,539
2927,Posterior cingulate glucose metabolism,539
795,Brain glucose metabolism,539
2806,Parietal cortex glucose metabolism,539
796,Brain metabolic function,539
4001,cerebral metabolic rate of oxygen (CMRO2),539
1956,I-ADL,540
153,ADL decline,540
145,ADCS-ADL,540
149,ADCS-IADL,540
148,ADCS-CGIC,540
147,ADCS-ADL23,540
154,ADLs,540
2090,Instrumental ADL performance,540
150,ADL,540
1741,Gcerebral,541
1742,Gcerebral spinal fluid,541
1691,GMcerebral spinal fluid,541
2178,LDL levels,542
1826,HDL/LDL,542
2176,LDAM,542
2181,LDR,542
2179,LDL-C,542
2981,QDRS,542
1285,DMN connectivity changes,543
1312,Default Mode Network (DMN),543
1313,Default network dysregulation,543
1314,Default-mode network (DMN),543
1315,Default-mode network (DMN) disruption,543
1286,DMN disruptions,543
3157,SLC24A4/RIN3,544
3158,SLC2A1,544
3159,SLC2A4,544
3156,SLC24A4,544
75,6-CN-PiB,545
943,CNV amplitude,545
941,CNP520,545
940,CNB-001,545
942,CNV,545
3226,Semantic memory,546
2385,Memory,546
2236,Logical Memory,546
2237,Logical Memory (WMS-III),546
2238,Logical Memory I (LMI) and II (LMII) from the Wechsler Memory Scale-Abbreviated (WMS-a),546
1965,ICAM-1,547
1966,ICAM1,547
2044,Icam1,547
2567,Neuritic plaques,548
1347,Diffuse plaques (DPs),548
3229,Senile plaques,548
2568,Neuritic plaques (NPs),548
4327,neuritic plaques,548
2328,MRI volumetric,549
2312,MRI (Whole-brain volume percentage change),549
2324,"MRI measures (hippocampus and ERC volumes, temporal lobe cerebral glucose metabolism)",549
3812,Whole brain volume on volumetric MRI (vMRI),549
2311,MRI (Hippocampi and ventricles volumes),549
3751,Voxel-based specific regional analysis system for Alzheimer's disease (VSRAD) scores,549
2320,MRI hippocampal volume,549
3750,Volumetric MRI,549
799,Brain volume (MRI),549
2684,P2Y12,550
2685,P2Y12 receptor,550
2686,P2ry12,550
2679,P2RY12,550
2884,Plasma Aβ(1-40),551
2889,Plasma Aβ42/40,551
2886,Plasma Aβ(1–42),551
2887,Plasma Aβ40,551
2888,Plasma Aβ42,551
2890,Plasma Aβx–40 levels,551
4434,plasma Aβ,551
2881,Plasma Aβ,551
2882,Plasma Aβ markers,551
2885,Plasma Aβ(1–40),551
28,18F-PI-2620,552
3193,SUVR 18F-FDG,552
30,18F-PI-2620 SUVR in fusiform gyrus,552
29,18F-PI-2620 SUVR,552
17,18F-AV45 SUVR,552
3745,Vitamin D,553
50,25-hydroxyvitamin D (25OHD),553
3746,Vitamin D (25OHD),553
3761,WLA,554
1833,HLA-DR expression,554
1832,HLA-DR,554
1831,HLA,554
810,Bridging integrator 1 (BIN1),555
705,BIN1,555
706,BIN1 risk variant,555
2629,N‐p‐tau181,40
4353,p-Tau (Thr181),40
438,p-tau181ADx,40
4372,p-tau181Fuji,40
4373,p-tau181P,40
4375,p-tau181p,40
2676,P181 tau (ptau),40
4398,pT181 tau protein,40
2666,P-tau181P,40
2665,P-tau181,40
3505,Tau (t-tau and p-tau181),40
4559,tau-p181,40
4367,p-tau181,40
2675,P181 tau,40
4357,p-Tau181,40
2422,Mid-p-tau181,40
4464,p‐tau181,40
4530,t-Tau and p-tau181,40
2425,Mid‐p‐tau181,40
2484,N-p-tau181,40
1879,High CS levels,557
984,CSS,557
964,CS Del,557
965,CS Imm,557
774,Bluish BL with high CS level,557
724,Basal Ganglia Volume,558
727,Basal ganglia,558
3051,Reduced DAT uptake in basal ganglia,558
4317,n-3 PUFA,559
4318,n-3 PUFAs,559
4319,"n-3 PUFAs (22:6n-3, total n-3)",559
4324,n3-PUFAs,559
2793,PUFAs,559
2645,Omega-3 PUFAs,559
2901,Plasma PUFA index,559
281,Abeta,560
106,ABeta42/40,560
105,ABeta42,560
282,Abeta-42,560
2295,MMP9,561
2294,MMP10,561
2293,MMP-9,561
1258,DA9,561
161,AKAP9,561
2742,PGE2,562
2963,Prostaglandin E2 (PGE2),562
4394,pGlu-CCL2,562
2741,PGC-1α,562
4395,pGluAB42,562
3701,Valeric Acid,563
3702,Valeric acid,563
4591,valeric acid,563
3057,Reduced uptake on metaiodobenzylguanidine myocardial scintigraphy,564
8,123iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy,564
1769,Global efficiency,565
4174,global efficiency,565
1765,Global Efficiency (GE),565
4116,efficiency,565
3350,Surface Area (SA),566
1210,Cortical Surface Area,566
1216,Cortical surface area,566
2992,Quantitative EEG analysis,567
1413,EEG phase,567
1408,EEG abnormalities,567
1416,EEG/ERP tasks,567
1412,EEG oscillatory activity,567
2993,Quantitative Electroencephalography (QEEG),567
1414,EEG spectral parameters (fast frequency bands),567
3264,Slow oscillatory brain activity,567
1411,EEG microstates,567
1456,Electroencephalography (EEG),567
1415,"EEG-based measures (ERPs, spectral band-power)",567
1410,EEG markers,567
1407,EEG,567
2193,Language,568
4232,language production,568
4509,speech/language alterations,568
4231,language comprehension,568
3291,"Speech characteristics (sentence complexity, verbal fluency)",568
2931,Pragmatic Language Function,568
2227,Linguistic density,568
2194,Language severity,568
3052,Reduced Sentences,568
1605,Fluent but Empty Speech,568
2051,IgG response,569
2055,IgG2,569
2056,IgG3,569
2057,IgG4,569
2053,IgG1,569
2052,IgG titres,569
2046,IgG,569
1298,DSF,570
1299,DSG2,570
1300,DSM criteria,570
1297,DSB,570
2509,NFL,58
2602,NfL levels,58
2899,Plasma NfL,58
2598,NfL,58
2726,PEDF,572
2867,Pigment epithelium-derived factor (PEDF),572
80,BNDF,572
1677,GDF-15,572
2611,Nitric oxide synthase,573
2610,Nitric oxide (NO),573
2911,Plasma nitric oxide (NO),573
128,DCX,574
1270,DCS,574
1267,DC25,574
1266,DC11,574
2338,MS4A6A,575
2337,MS4A4A,575
2336,MS4A,575
3834,ZCWPW1,576
3837,ZO-1,576
2646,Omni-z,576
3833,ZBI,576
1604,Flt1,577
1549,FLT1,577
1603,Flt-1,577
1307,Da,578
672,BAD,578
165,ALA,578
2480,N,578
2527,NO,578
1256,DA,578
1262,DAM,578
2774,PS,578
1937,Hub location,579
1938,Hub strength,579
118,Cognitive reserve change score (CRCS),580
1170,Cognitive reserve (CR),580
1159,Cognitive Reserve (CR),580
3416,TLR2,581
3574,Tlr2,581
3418,TLR3,581
3419,TLR4,581
3417,TLR2/4,581
3145,SFS,582
3144,SFN,582
3143,SFA,582
2824,Perivascular Spaces,583
2825,Perivascular spaces,583
3066,Renin-angiotensin system,584
181,ANGP-2,584
453,Angiopoietin,584
182,ANGPT1,584
86,8-oxodG/8-oxoGuo,585
85,8-oxodG,585
84,8-oxoGuo,585
2638,OXPHOS complex levels,585
2662,Oxytocin,585
767,Blood glucose,586
45,2-deoxy-D-glucose (2DG),586
3062,Regional glucose metabolism,586
3964,blood glucose,586
1772,Glucose,586
1773,Glucose metabolism,586
1066,Cerebral glucose uptake,586
3343,Sugar intake,586
1775,Glucose metabolism levels,586
1776,Glucose metabolism rates,586
1777,Glucose uptake,586
4175,glucose metabolism,586
4176,glucose uptake,586
1758,Gingko biloba,587
1759,Ginsenoside Rb1,587
1760,Ginsenosides,587
2670,P. gingivalis,587
2925,Porphyromonas gingivalis infection,587
1757,Gingipains,587
418,gingipains,587
268,P. gingivalis DNA,587
1048,Cerebelum_8_R (aal),588
1047,Cerebelum_8_R,588
1046,Cerebelum_8_L (aal),588
2136,JAK2,589
2137,JAK3,589
2140,JNK1,589
2135,JAK1,589
2141,Jag1,589
2148,Kcnk1,589
3778,WML load,590
3776,WML,590
82,8-hydroxy-2′-deoxyguanosine (8-OHdG),591
83,8-hydroxydeoxyguanosine (8-OHdG),591
66,4-hydroxyhexenal (4HHE),591
2404,Methoxy-X-O4,591
44,2'-deoxyguanosine,591
170,ALFF/fALFF,592
18,ALFF/fALFF levels,592
168,ALFF,592
55,2DG uptake,593
22,18F-FDG uptake,593
1524,FDG uptake,593
81,8-OHdG,594
51,25OHD,594
80,8-OHDG,594
49,24OH,594
3108,Rivastigmine,595
4477,rivastigmine,595
4491,sTNFR2,596
4492,sTREM2,596
4490,sTNFR1,596
1441,ERP measures,597
1440,ERP,597
1438,ERN,597
4339,neutrophils,598
2596,Neutrophils,598
2595,Neutrophil,598
2035,IRS1,599
2034,IRS-1/2,599
2033,IRS-1,599
2036,IRS2,599
2037,IRSP,599
2032,IRS,599
2410,Microbleed presence,600
4296,microbleeds,600
2411,Microbleeds,600
2362,Matrix metalloproteinases,601
2401,Metalloproteinases,601
2183,LOC101929163,602
704,BI 409306,602
2184,LOC399491,602
2139,JNJ-54861911,602
1848,HSD17B11,602
1706,GSK2647544,602
180,GSK933776,602
275,AZD3293,602
2702,PAC001381_s,602
274,AZD0530,602
3135,SCP VD (parafoveal),603
2799,Parafoveal SCP AFI,603
2800,Parafoveal SCP VD,603
839,CA4 volume,604
838,CA3 volume,604
837,CA2+3 Volume,604
836,CA1 volume,604
4229,lacunes,605
2192,Lacunes,605
2970,Psoriasis,606
454,Ankylosing Spondylitis,606
178,Glucocorticoid Production,606
1941,Hypercortisolism,606
3097,Rheumatoid Arthritis,606
588,Aβ1-37,8
537,Aβ 1-42,8
599,Aβ1-x,8
609,Aβ1–42/Aβ1–40 ratio,8
602,Aβ1–37,8
608,Aβ1–42/Aβ1–40,8
603,Aβ1–38,8
536,Aβ 1-40,8
607,Aβ1–42,8
530,AΒ1-42,8
606,Aβ1–40 and Aβ1–42 serum levels,8
4302,mitochondrial Aβ1–40 levels,8
605,Aβ1–40 and Aβ1–42,8
604,Aβ1–40,8
554,Aβ levels (Aβ1−40 and Aβ1−42),8
58,Aβ(1-40),8
598,Aβ1-43,8
572,Aβ(1–40),8
587,Aβ1-34,8
586,Aβ1-16,8
591,Aβ1-42,8
592,Aβ1-42 expression,8
593,Aβ1-42/1-40,8
585,Aβ1-15,8
589,Aβ1-38,8
594,Aβ1-42/1-40 (blood-based),8
584,Aβ1-14,8
595,Aβ1-42/Aβ1-40,8
596,Aβ1-42/Aβ1-40 ratio,8
573,Aβ(1–42),8
590,Aβ1-40,8
3246,Silent lacunar infarcts (SLIs),608
2190,Lacunar infarct,608
2191,Lacunar infarcts,608
2189,Lacunar Infarcts,608
2753,PICALM SNP rs541458,609
2752,PICALM SNP rs3851179,609
1552,FOXF2,610
1619,Foxp3,610
1618,FoxO,610
2428,Mini Geriatric Depression Scale,611
1753,Geriatric Depression Scale (GDS),611
1752,Geriatric Depression Scale,611
300,Actigraphy measurements,612
299,Actigraphy,612
4424,phospho-p38,613
4416,phospho-AKT,613
4419,phospho-JNK,613
4417,phospho-ERK,613
4422,phospho-PKCα,613
4421,phospho-PKA,613
9,129Xe,614
13,129Xe-GM,614
1843,HP 129Xe,614
951,COX2,615
949,COX-1,615
948,COX,615
950,COX-2,615
4523,synaptic toxicity,616
4521,synaptic dysfunction,616
4520,synaptic density,616
3362,Synaptosomal associated protein 25,616
3357,Synaptic dysfunction biomarkers,616
3358,Synaptic proteins,616
3359,Synaptic strength and plasticity measures,616
4522,synaptic proteins and BDNF,616
4636,γ-secretase complex,617
3957,beta secretase 1 protein (BACE-1),617
3958,beta secretase I,617
4631,β-secretase,617
744,Beta secretase-I,617
664,BACE (β-secretase),617
746,Beta-secretase activity,617
258,ATP content,618
257,ATP,618
3214,Sarkosyl-insoluble tau,619
3213,Sarkosyl-insoluble Tau,619
3215,Sarkosyl-soluble Tau,619
1723,Gal-1,620
4242,let-7,620
1841,HOP,620
3166,SNAP-25,620
1673,GAS-10,620
3572,Tie-2,620
2138,JAM-1,620
1281,DJ-1,620
1842,HOP-1,620
4138,filled pauses,621
3954,be quiet,621
2073,Increased silent pauses,621
3623,Trailing Off,621
1884,High-density lipoprotein (HDL),622
2177,LDL cholesterol,622
2241,Low-density lipoprotein (LDL),622
1823,HDL cholesterol,622
2180,LDL-cholesterol,622
3640,Triglycerides/HDL-cholesterol ratio,622
773,Blood-markers,623
765,Blood cell count,623
770,Blood samples,623
1186,Complete Blood Count (CBC),623
3794,White blood cell count,623
2124,Irritability,624
2466,Mood,624
2818,Perceived stress levels,624
2999,RAGE,624
3312,Stress,624
1372,Dispersion-based methodology,625
138,Dispersion,625
2653,Overall Pathology,626
2654,Overall pathology,626
1188,Compliance,627
2379,Medication Compliance,627
1384,Drp1,628
1836,HLA-DRB5/HLA-DRB1,628
1835,HLA-DRB1,628
1294,DRG1,628
3444,TNFα,629
3443,TNFSR1A,629
3442,TNFR2,629
3437,TNF-α,629
3440,TNFR1,629
3576,Tnf,629
3430,TNF,629
3431,TNF blockers,629
3432,TNF blocking agents,629
3433,TNF-a,629
3434,TNF-alfa,629
3435,TNF-alpha,629
3436,TNF-proteins,629
3439,TNF-β,629
3441,TNFR1 signaling,629
1391,Dyslipidemia,630
1942,Hyperlipidemia,630
2555,Naïve T cells,631
2391,Memory T cells,631
338,T cells,631
3402,TEMRA T cells,631
3373,T-cells,631
1725,Galantamine,632
1726,Galectin-1 (Gal-1),632
4310,mitofusin-2,632
1724,Galactin-3,632
496,Aquaporin-4,632
1727,Galectin-3,632
1232,Creatine+Phosphocreatine,633
1231,Creatine kinase,633
1233,Creatinine,633
2077,Inferior frontal lobe grey matter volume,634
1804,Grey Matter Density in Temporal Lobe,634
1807,Grey matter density in medial temporal lobe,634
1803,Grey Matter Density in Hippocampus,634
797,Brain structure (grey matter density and amygdala volume),634
2792,PU-HZ151,635
2791,PU-H8,635
3848,[124I]-PU-H8,635
3849,[124I]-PU-HZ151,635
3340,Subjective Memory Complaints (SMC),636
2388,Memory Complaints Scale (MCS),636
3341,Subjective Memory Complaints (SMCs),636
3299,Stages of Objective Memory Impairment (SOMI),636
2387,Memory Awareness Rating Scale-Memory Functioning (MARS-MF),636
3339,Subjective Memory Complaint (SMC),636
395,Amyloid SUVR,637
396,Amyloid SUVr,637
409,Amyloid burden (SUVR),637
3897,amyloid PET SUVr,637
385,Amyloid PET SUVr,637
3697,VQIINK motif,638
1744,Gene expression profiles,638
3953,bche gene,638
4204,hmuY gene,638
62,390-gene co-expression module,638
4640,θ−β1,639
4641,θ−γ,639
4639,θ−α2,639
4227,ioflupane (123I),640
2120,Ioflupane (123I),640
3154,SIRT1,641
3251,Sirt1,641
1739,Gbp2,642
1740,Gbp6,642
1675,GBS,642
1674,GBA,642
1328,Deltaproteobacteria,643
2967,Proteobacteria,643
167,ALCAR,644
172,ALK,644
166,ALB,644
2590,"Neuropsychiatric Inventory, 10-item total score",645
2589,Neuropsychiatric Inventory (NPI),645
2588,Neuropsychiatric Inventory,645
2569,Neuro-Psychiatric Inventory (NPI),645
3315,Stride Time Variability (STV),646
1155,CoV of stride time,646
3319,Stride time variability (CVst),646
3320,Stride time variability (CoV),646
1156,Coefficient of Variation (CoV) of stride time,646
247,AST,647
246,ASC,647
245,AS,647
4195,hippocampal volume,648
3065,Relative volume of left hippocampus,648
1920,Hippocampus volumes,648
1919,Hippocampus volume loss,648
1909,Hippocampal volume rate of change,648
1918,Hippocampus volume,648
4200,hippocampus volume,648
1892,Hippocampal Volume,648
1893,Hippocampal Volume (HV),648
1905,Hippocampal subfield volume,648
4473,right hippocampus volume,648
1906,Hippocampal volume,648
3104,Right hippocampus volume,648
1908,Hippocampal volume loss,648
2210,Left hippocampal volume,648
4194,hippocampal subfield morphometry and volumetry,648
1910,Hippocampal volume reduction,648
1911,Hippocampal volumetry,648
1907,Hippocampal volume (HV),648
2798,Para-hippocampal volume,648
2507,NFKBIA,649
2508,NFKBIZ,649
2604,Nfkb2,649
3669,Ubiquitin-mediated proteolysis,650
4587,ubiquitin,650
3668,Ubiquitin,650
3670,Ubiquitinated proteins,650
2329,MRI-based atrophy measurements,651
513,Atrophy on MRI,651
3944,atrophy rate measured from structural MRI,651
1899,Hippocampal atrophy on MRI,651
2317,MRI atrophy rates,651
2314,MRI Temporal Atrophy,651
2325,MRI measures of cerebral atrophy,651
787,"Brain MRI (regional atrophy in frontal, parietal, temporal structures)",651
1060,Cerebral atrophy on MRI,651
2321,MRI markers (regional cerebral atrophy),651
2345,MTOR,652
4256,mTOR,652
4257,mTOR kinase,652
4259,mTORC1 activation,652
2096,Insulin (INI),653
2118,Intranasal Insulin (INI),653
2119,Intranasal insulin (INI),653
1350,Digit Span,654
1352,Digit span forward,654
1354,Digit span test,654
1355,Digit-span,654
1353,Digit span forward test,654
31,18F-PI-2620 SUVR in inferior temporal cortex,655
32,18F-PI-2620 SUVR in mesial temporal cortex,655
34,18F-PI-2620 SUVR in superior temporal cortex,655
33,18F-PI-2620 SUVR in occipital cortex,655
3223,Semantic Deficits,656
3224,Semantic Fluency,656
2220,Lexical and semantic retrieval deficits,656
3227,Semantic word fluency,656
2026,IP-10,657
4216,inferior parietal lobule (IPL),657
2028,IPL,657
2076,Inferior Parietal Lobule (IPL),657
3755,WBC,658
3788,White Blood Cell (WBC),658
3789,White Blood Cells (WBC),658
3756,WBC count,658
3824,Working Memory/Attention/Executive Control (ExecCon),659
3823,Working Memory/Attention/Executive Control,659
3825,Working memory,659
3822,Working Memory/Attention,659
2280,MFIp75NTR,660
4391,p75,660
4392,p75NTR,660
301,Actin,661
306,Activin A,661
111,ACTH,661
3620,Trail Making Test Part B,662
3621,Trail Making Test part B,662
3622,Trail-Making Test-B,662
3617,Trail Making Test (TMT) times,662
3613,Trail Making B test,662
3618,Trail Making Test A,662
3614,Trail Making Test,662
3619,Trail Making Test B,662
1193,Comprehensive Trail Making Test (TMT),662
3615,Trail Making Test (TMT) A and B,662
3616,Trail Making Test (TMT) parts A and B score,662
464,Apathy (NPI),663
465,Apathy Inventory,663
2540,NPI-Q Apathy,663
466,Apathy Scale (AS),663
1363,Dimensional Apathy Scale (DAS),663
3955,behavioural markers of apathy,663
3928,apathy,663
463,Apathy,663
1067,Cerebral hypometabolism on FDG PET,664
1531,FDG-PET hypometabolism,664
1526,FDG-PET Hypometabolism,664
1477,Epichaperomes,665
4129,epichaperome probes,665
2949,"Pro-inflammatory cytokines (e.g., TNF-α)",666
766,Blood cytokine levels,666
2082,Inflammatory cytokines,666
4092,cytokines,666
1248,Cytokine and chemokine signatures,666
1249,Cytokines,666
4091,cytokine levels,666
4213,immune cytokines,666
2948,Pro-inflammatory cytokines,666
2954,Proinflammatory cytokines,666
2955,"Proinflammatory cytokines (IL-1, IL-6, TNF-alpha, TGF-beta)",666
977,CSF cytokine levels,666
4218,inflammatory cytokines,666
3642,Triterpenoid saponins (TT),667
3641,Triterpenes (TT),667
2910,Plasma malondialdehyde (MDA),668
2358,Malondialdehyde (MDA),668
978,CSF p-tau,40
981,CSF t-tau,40
4533,t-tau in CSF,40
975,CSF P-Tau,40
979,"CSF p-tau (T181, T217, T231)",40
4361,p-tau in CSF,40
4368,p-tau181 (CSF),40
980,CSF p-tau(181),40
4463,p‐tau (PHF),40
982,CSF tau,669
663,BACE,670
666,BACE enzyme,670
668,BACE2,670
667,BACE1,670
665,BACE activity,670
1149,Clock drawing,68
1151,Clock-drawing test,68
1148,Clock Test,68
1150,Clock-Drawing Test,68
1146,Clock Drawing test,68
1145,Clock Drawing Test,68
2541,NPI-Q Depression,672
2535,NPI-NH Affective symptoms,672
2536,NPI-NH Agitation,672
2537,NPI-NH Psychosis,672
168,GAD67-positive interneurons,673
1664,GABAergic interneuron numbers,673
1665,GABAergic interneurons,673
3282,Somatostatin-positive interneurons,673
4190,hilar GABAergic interneurons,673
1275,DEMQoL scale,674
1274,DEMQOL,674
4541,tTau/Aβ1-42 ratio,675
4458,ptau/Aβ1–42,675
4542,tTau/Aβ42,675
4402,pTau/Aβ42,675
4401,pTau/Aβ1-42 ratio,675
636,Aβ42/ttau ratio,675
635,Aβ42/ttau,675
4540,tTau/Aβ1-42,675
176,AMPA,676
4348,p-AMPK,676
177,AMPK,676
4446,precuneus,677
2938,Precuneus_R,677
4476,right precuneus,677
2933,Precuneus,677
3914,amyloid-β (Aβ),8
429,Amyloid β-protein (Aβ),8
649,Aβo (oligomeric amyloid beta),8
433,Amyloid-beta (Aβ),8
745,Beta-amyloid (Aβ),8
425,Amyloid β (Aβ),8
443,Amyloid-β (Aβ),8
378,Amyloid (Aβ oligomers),8
325,Aggregated Aβ,8
545,Aβ amyloid fibrils,8
534,Aβ (amyloid deposition),8
4624,β-amyloid aggregates,8
535,Aβ (amyloid-beta),8
532,Aβ (Amyloid Beta),8
380,Amyloid Beta (Aβ),8
399,Amyloid beta (Aβ),8
414,Amyloid oligomers,8
4623,β-amyloid (Aβ),8
1213,Cortical amyloid β (Aβ) deposition,8
3053,Reduced blood flow in posterior cingulate gyrus/precuneus,679
3058,Reduction in blood flow in the posterior cingulate gyrus and/or precuneus,679
963,CRY2,680
962,CRY1,680
1646,Functional Independence Measure,681
4157,functional independence,681
6,11β-HSD1,682
7,11β‐HSD1,682
5,11C-Pittsburgh compound B (PiB) PET uptake,683
288,Pittsburgh compound B (PiB),683
2870,Pittsburgh compound B (PIB),683
2869,Pittsburgh Compound-B (PiB) SUVR,683
2736,PET with Pittsburgh Compound B (PIB),683
3839,[11C]-Pittsburgh Compound B PET (PiB-PET),683
1111,ChAT activity,684
1110,ChAT,684
4335,neurogranin levels,685
2582,Neurogranin (in CSF),685
4334,neurogranin,685
2581,Neurogranin,685
1139,Clinical Dementia Rating Sum of Boxes (CDR-SB),686
1138,Clinical Dementia Rating Scale (CDR),686
1136,Clinical Dementia Rating (CDR),686
1141,Clinical Dementia Rating scale-Sum of Boxes (CDR-SB),686
1142,Clinical dementia Rating (CDR),686
1137,Clinical Dementia Rating (CDR) scores,686
1143,Clinical dementia Rating–sum of boxes (CDR-SB),686
857,CCH,687
295,Ach,687
112,ACh,687
3221,Selective serotonin reuptake inhibitors (SSRIs),688
73,5-HT6 receptor antagonist,688
3232,Serotonin (5-HT),688
3870,[18F]florbetaben,689
27,18F-Flortaucipir (18F-AV1451),689
37,18F-flortaucipir,689
36,18F-florbetapir,689
3873,[18F]flortaucipir,689
24,18F-Florbetaben,689
26,18F-Florbetapir,689
3850,[18F] florbetapir,689
388,[18F]florbetapir,689
25,18F-Florbetaben SUVR,689
4143,florbetapir F 18,689
3872,[18F]florbetapir SUVR,689
2624,Number of medications,690
2625,Number of medications (NMED),690
2721,PDGFRB,691
2720,PDGFR,691
2722,PDGFRα,691
289,PDGF,691
15,18F-AV-1451,692
259,AV-1451,692
16,18F-AV-1451 (tau),692
260,AV-1451 PET,692
2813,Pause Length,693
3300,Standard Pause Rate,693
2239,Longer pause duration,693
3293,Speech rate and pause characteristics,693
2267,MDA,694
2268,MDA levels,694
2270,MDC,694
72,5 LOX,695
74,5-LOX,695
2352,Madecassoside,696
4260,madecassic acid,696
2351,Madecassic acid,696
3658,UBQLN2,697
3657,UBQLN1,697
1952,Hyperspectral (HS) score,698
1951,Hyperspectral (HS) imaging,698
3002,RANTES/CCL5,699
3001,RANTES,699
1103,Ch1/2 subfield volume,700
1109,Ch4p subfield volume,700
1107,Ch4a-i subfield volume,700
1104,Ch3 subfield volume,700
2550,NSP subfield volume,700
2525,NMED,701
2524,NME8,701
2390,Memory Impairment Screen (MIS-T),702
2389,Memory Impairment Screen (MIS),702
187,Gait Velocity,703
189,Gait speed,703
1721,Gait velocity,703
1722,Gait-speed,703
4162,gait speed,703
4164,gait velocity,703
3263,Slow gait speed,703
186,Gait Speed,703
1834,HLA-DR surface expression,704
873,CD39 surface expression,704